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‘Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less.’ 
     







Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common 
form of dementia. Accumulation of AD-associated pathology in the brain may begin a decade 
or more before the appearance of the first symptoms of the disease. The pathological-clinical 
“continuum of AD” therefore encompasses time between the initial neuropathological changes 
and symptoms of advanced disease. Besides cognitively healthy individuals at risk, it includes 
subjects with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and 
eventually dementia when the severity of cognitive impairment affects patients’ ability to carry 
out everyday activities. Timely detection of the disease would therefore recognize patients that 
are at risk for future cognitive deterioration and provide time window for the prevention and 
novel therapeutical interventions. Accumulating evidence suggests that degeneration and 
dysfunction of brain neuronal connections, i.e. synapses, is one of the earliest and best proxies 
of cognitive deficits in patients along AD continuum. Human electroencephalography (EEG) 
is a non-invasive and widely available diagnostic method that records real-time large-scale 
synaptic activity. The commonly used method in research settings is quantitative EEG (qEEG) 
analysis that provides objective information on EEG recorded at the level of the scalp. 
Quantitative EEG analysis unravels complex EEG signal and adds relevant information on its 
spectral components (frequency domain), temporal dynamics (time domain) and topographic 
estimates (space domain) of brain cortical activity. The general aim of the present thesis was 
to characterize different aspects of synaptic degeneration in AD, with the focus on qEEG and 
its relationship to both conventional and novel synaptic markers. In study I, global qEEG 
measures of power and synchronization were found to correlate with conventional 
cerebrospinal fluid (CSF) biomarkers of Aβ and tau pathology in patients diagnosed with SCD, 
MCI and AD, linking the markers of AD pathology to the generalized EEG slowing and 
reduced brain connectivity in fast frequency bands. In study II, qEEG analysis in the time 
domain (EEG microstates) revealed alterations in the organization and dynamics of large-scale 
brain networks in memory clinic patients compared to healthy elderly controls. In study III, 
topographical qEEG analysis of brain functional connectivity was associated with region-
specific cortical glucose hypometabolism ([18F]Fluorodeoxyglucose positron-emission 
tomography) in MCI and AD patients. Study IV provided evidence that qEEG measures of 
global power and synchronization correlate with CSF levels of synaptic marker neurogranin, 
both modalities being in combination independent predictors of progression to AD dementia 
in MCI patients. Study V and associated preliminary study introduced in the thesis assessed the 
translational potential of CSF neurogranin and qEEG as well as their direct relationship to AD 
neuropathology in App knock-in mouse models of AD. In study V, changes in CSF neurogranin 
levels and their relationship to conventional CSF markers in App knock-in mice corresponded 
to the pattern observed in clinical AD cohorts. These findings highlighted the potential use of 
mouse CSF biomarkers as well as App knock-in mouse models for translational investigation 
of synaptic dysfunction due to AD. In general, the results of the thesis invite for further clinical 
validation of multimodal synaptic markers in the context of early AD diagnosis, prognosis, and 
treatment monitoring in individual patients. 
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1.1 FROM NORMAL BRAIN AGING TO NEURODEGENERATION 
The global population aged 65 years or over has doubled in the last 30 years. The number of 
elderly people is expected to further increase and reach over 1.5 billion by 2050 (1). A positive 
trend in worldwide population aging is one of the great achievements of humankind. Still, our 
brain is not resistant to aging, since it is characterized by functional and structural changes such 
as age-related cognitive decline, grey and white matter atrophy, impairment of functional 
connectivity and neurotransmission (2). These alterations are often subtle, non-progressive, and 
do not result in functional impairment (2). However, advanced age and increased complexity 
of cognitive functions developed during the evolution of the human brain may have accentuated 
vulnerabilities of our species, including susceptibility to multifactorial neurodegenerative 
disorders (3). 
1.1.1 Continuum of Alzheimer’s disease (AD) 
Dementia is a neurocognitive disorder associated with old age. In the world aging population, 
Alzheimer’s disease (AD) is the most common form of dementia characterized by a progressive 
cognitive decline that ultimately affects the ability to carry out everyday activities (4, 5). 
Quantitative and qualitative differences between normal aging and AD dissociate AD as an 
entity with disease-related changes in the brain structure and function (2). These AD-associated 
brain changes may begin a decade or more before first clinically evident symptoms appear. 
Consequently, the “continuum of AD” refers to the time between the initial brain changes and 
symptoms of advanced disease (6). Besides cognitively healthy individuals at risk, the 
continuum of AD includes subjects that experience a self-perceived decline in cognition with 
a performance on cognitive testing within the range of a normal variation, which is referred to 
as subjective cognitive decline (SCD) (7). A proportion of SCD individuals may represent the 
incipient stage of AD since it has been shown that they have an increased probability of AD 
biomarker positivity and future cognitive decline (7-11).  
Further along the continuum, individuals have mild but objectively measurable deficits in one 
or more cognitive domains that still do not affect the ability to carry out everyday activities, 
referred to as mild cognitive impairment (MCI) (6, 12). MCI has been identified as an at-risk 
condition, with an annual transition rate to dementia of 8% to 15% (13). The variability in the 
reported transition rates stems presumably from different clinical and/or research diagnostic 
criteria used across studies.  
SCD and MCI subjects comprise a substantial percentage of memory clinic patients (Figure 1). 
However, in the absence of supportive biomarkers, they represent rather heterogeneous 
conditions that differ in neuropathology, clinical presentation, and long-term prognosis, with a 
substantial number of patients remaining cognitively stable over time (14). Furthermore, the 
trajectory of decline in subjects with the same biological risk may be different due to individual 
variability in functional capacity determined by the brain and cognitive reserve (15). Since the 
disease’s biological processes can be diagnosed in the early clinical stages without considerable 
functional impairment, the most recent clinical diagnostic criteria, DSM-5, are proposing 
 
2 
grading of neurocognitive impairment from minor to major and exclusion of dementia as a 
diagnostic term (16). 
 
 
Figure 1. Distribution of diagnoses at Memory Clinic, Karolinska University Hospital 
Huddinge, Sweden. The colored portions represent the percentage (%) of diagnoses of the total 
number of 270 patients during January – October 2020. AD = Alzheimer’s disease; DLB = 
dementia with Lewy bodies; FTD = frontotemporal dementia; MCI = mild cognitive 
impairment; PDD = Parkinson's disease dementia; SCD = subjective cognitive decline; VaD 
= vascular dementia. 
1.1.2 Neuropathology in AD 
German psychiatrist and neuropathologist Alois Alzheimer was the first to identify and 
describe typical neuropathological changes of the disease that bears his name. Distinctive 
plaques and neurofibrillary tangles remain the neuropathological hallmarks of AD to date 
(17). The main component of the extracellular plaques is amyloid β protein (Aβ) produced 
from a larger amyloid β precursor protein (APP) by the consecutive cleavage by β- and γ-
secretase (18). According to the amyloid cascade hypothesis, an imbalance between 
production and clearance of highly self-aggregating Aβ42 is an early and most likely 
initiating factor of AD (19, 20). The majority of AD cases are sporadic (sAD) with a minority 
of patients suffering from familial AD (fAD) caused by mutations within the APP or the γ-
secretase component presenilin (PSEN) gene that alter APP processing and result in elevated 
levels or more aggregation-prone forms of Aβ42 (21-23). The main known genetic risk factor 
for sAD is the apolipoprotein E (APOE) ε4 genotype (24). According to the comprehensive 
meta-analysis, homozygous APOE ε4 carriers have 2 – 33 fold increased risk of sAD which 
is thought to be mediated by the effect of the ε4 allele on Aβ deposition and clearance, 
maintenance of neuronal and synaptic function, and neuroinflammation (25, 26). Duplication 
of the wild-type APP gene, due to the 21 trisomy in Down’s syndrome, leads to increased Aβ 
deposition and typical Alzheimer neuropathology, further supporting the amyloid hypothesis 
(27). The distribution of Aβ deposition during the course of AD follows a certain sequence, 
involving the neocortex, followed by the hippocampus and entorhinal cortex, diencephalic 
nuclei and striatum, cholinergic nuclei of the basal forebrain, brainstem and finally 
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cerebellum (28, 29). Another hallmark of AD neuropathology is the intraneuronal 
accumulation of abnormally phosphorylated tau protein that results in the formation of 
intracellular neurofibrillary tangles (NFT) (30). In AD, referred tau pathology starts with the 
“transentorhinal” and “limbic stages” and ends with a widespread “isocortical stage” (29). 
Regional distribution of tau pathology additionally correlates well with the 
neurodegeneration as well as the severity of cognitive impairment (31-33). Since most of the 
neuropathological studies included patients with advanced, end-stage of AD, the 
development and implementation of early and reliable disease-specific biomarkers will 
further elucidate the clinicopathological trajectory of AD continuum. 
1.1.3 Synaptic dysfunction in AD 
Decreased brain synaptic density appears to be a consistent finding and the closest anatomical 
correlate of cognitive impairment in AD (34-36). Several studies have reported substantial loss 
of synapses in the hippocampus and neocortex early during the disease course, present already 
in the MCI stage (34-39). Besides, loss of synapses appears to be more substantial than 
neuronal loss in the same brain regions (37). These discoveries suggested that AD might be 
primarily a disease of synaptic failure (40, 41). In addition, it raised interest in downstream 
mechanisms of AD pathological processes that have selective toxic effects on synapses (40, 
42).  
Recent findings point towards soluble Aβ42 oligomers as the most toxic amyloid species in the 
brain (19, 43, 44). It has been shown that Aβ oligomers can dose-dependently impair long term 
potentiation (LTP), decrease dendritic spine density, and deplete number of brain synapses (43-
46). Moreover, cognitively healthy individuals with an abundance of amyloid plaques in the 
brain may have low Aβ oligomer levels (low oligomer-to plaque ratios), which might represent 
a missing link in understanding the (lack of) relationship between amyloid burden in the brain 
and cognition (19, 47). It has been proposed that Aβ42 oligomers have the potential to drive 
AD-like tau pathology since they can induce tau hyperphosphorylation and neuritic 
degeneration (48). Moreover, tau pathology can induce synaptic alterations independent of Aβ 
accumulation as shown in the mouse models of tauopathy (49-51). Activation of microglia and 
astrocytes that accompanies buildup of Aβ and tau pathology in the brain is an additional 
contributor to the synaptic degeneration and loss in AD (52-54). These recent findings raise 
compelling evidence that the key pathophysiological events leading to synaptic dysfunction 






Figure 2. Illustration of the key pathophysiological events leading to synaptic dysfunction in 
AD. Aβ oligomers exhibit synaptotoxic effects, form Aβ fibrils and extracellular amyloid 
plaques. Pathological forms of tau form intracellular neurofibrillary tangles and have an 
additional impact on synapses. Activation of microglia and astrocytes that accompanies Aβ 
and tau pathology is another contributor to the synaptic degeneration and loss in AD.  
1.1.4 Clinical and research diagnostic criteria 
Clinical diagnostic criteria define AD as a progressive disorder of middle or late life with an 
insidious onset and progressive deterioration of memory and other cognitive domains, in the 
absence of any other systemic or brain disease as a possible underlying cause of referred 
memory and/or other cognitive deficits (5, 55). Revised clinical criteria of National Institute on 
Aging-Alzheimer’s Association workgroups recognized AD dementia as a part of the 
continuum and referred to it as a fundamentally clinical diagnosis but emphasized the use of 
AD pathophysiological biomarkers in clinical trials and research settings (56). However, 
McKhann’s clinical diagnostic criteria underline post-mortem histopathological proved AD as 
a definite diagnosis of the disease (55-57). On the other hand, in 2007 International Working 
Group (IWG) published the research diagnostic criteria of AD that rely on the specific clinical 
phenotype (episodic memory impairment) and presence of supportive biomarkers that provide 
in vivo evidence of the disease. The aim was to incorporate biomarkers of AD, such as structural 
magnetic resonance imaging (MRI), molecular imaging with positron-emission tomography 
(PET) and conventional cerebrospinal fluid (CSF) AD biomarkers in order to recognize and 
detect the earliest stages of the disease (58). The IWG criteria were first refined in 2010, 
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proposing a distinction between the clinical disease and disease pathology which led to defining 
the preclinical stage of the disease as “asymptomatic at risk for AD” (involving biomarker 
positive but asymptomatic individuals) and “presymptomatic AD” (referring to autosomal 
dominant mutation carriers) (59). The IWG-2 further refined the research criteria in 2014 based 
on weighting of the biomarkers and defined typical AD as an entity with episodic memory 
impairment with the presence of in vivo supportive biomarkers of amyloid and tau pathology. 
Additionally, IWG-2 criteria outlined structural MRI and [18F]Fluorodeoxyglucose positron-
emission tomography ([18F]FDG-PET) as valuable markers of disease progression (60). A 
substantial number of ongoing studies have focused on the identification of novel AD 
biomarker candidates. Diagnostic modalities that prove to capture the earliest stages of the 
disease will presumably lead to further refinements of research and clinical diagnostic criteria. 
1.2 ALZHEIMER’S DISEASE BIOMARKERS 
The ongoing investigations of AD pathophysiological processes provide insights into new 
potential therapeutic strategies. Concurrently, they have urged the identification of reliable and 
translational biomarkers that reflect core elements of disease pathophysiology. A biomarker is 
an objective measure of a normal biological or pathogenic process used to guide clinical 
diagnosis, assess disease risk and prognosis, aid drug selection and monitor therapeutic 
interventions (61). Many studies have shown that biomarker abnormalities consistent with the 
central AD pathophysiological processes are detectable before the appearance of significant 
clinical symptomatology and are predictive of cognitive decline (Figure 3) (6, 61, 62). 
 
Figure 3. Proposed model of dynamic biomarker changes along Alzheimer's disease 
continuum. Adapted with permission from Sperling RA, Aisen PS, Beckett LA, et al. Toward 
defining the preclinical stages of Alzheimer's disease: recommendations from the National 
Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for 
Alzheimer's disease. Alzheimers Dement. 2011;7:280-292. © 2011 Published by Elsevier B.V. 
1.2.1 Conventional CSF biomarkers 
Cerebrospinal fluid (CSF) is a clear and proteinaceous fluid contained in the brain ventricular 
system and subarachnoidal space. It is continuously produced, reaching an average rate of 
around 500 mL per day in adult humans (63). CSF has a potential to reflect biochemical 
changes in the brain due to direct contact with its extracellular space (61). In addition to its 
flow through the brain ventricular system and into the subarachnoid space, CSF passes through 
 
6 
interstitial space of brain parenchyma, mixes with the extracellular fluid and carries away brain 
waste products (64). CSF, which can be directly obtained by a lumbar puncture, is therefore an 
easily accessible source of AD-associated biomarkers. 
Core CSF biomarkers of AD seem to reflect the underlying molecular pathology of the disease. 
CSF AD profile includes reduced concentrations of Aβ42 and increased total tau (t-tau) and 
phosphorylated tau (p-tau) protein levels (61, 65) (Figure 4). The general explanation for the 
reduction in CSF Aβ42 levels found in AD patients is that Aβ42 preferentially deposits in the 
brain tissue which leads to decreased diffusion of Aβ42 into the CSF (66). Reduced CSF Aβ42 
levels in patients along AD continuum were found to correlate well with cortical plaque load 
in the brain tissue (67-69) and in vivo brain amyloid load as detected by [11C]Pittsburgh 
Compound-B PET ([11C]PIB-PET) imaging (70-72). CSF Aβ42 positivity (i.e. reduction) in 
patients with cognitive impairment is indicative of underlying AD pathology (6, 61) and is 
predictive of increased rate of brain atrophy even in healthy elderly subjects (73).  
P-tau levels in the CSF presumably reflect phosphorylation state of tau and the development of 
neurofibrillary tangles in the AD brain (61, 74). CSF t-tau is considered a less specific AD 
marker compared to CSF p-tau as it is thought to mirror the intensity of neuronal and axonal 
damage in the AD brain (61) and is also increased in different acute states such as stroke and 
brain trauma (75, 76). Recently, the role of tau secretion in the brain and Aβ pathology-induced 
alterations in tau phosphorylation and release have been emphasized in several preclinical and 
clinical studies (77-80). Elevated CSF tau levels have been associated with faster cognitive 
decline (81, 82), progression from MCI to AD (83, 84) and cortical and hippocampal atrophy 
(85-87).  
Considerable progress has been recently made in regard to the blood-based biomarkers of core 
AD pathology. Even though additional efforts are needed to overcome challenges in their 
development and widespread clinical use, blood-based biomarkers may offer straightforward, 
non-invasive, and cost-effective detection of AD pathology (88). 
 
Figure 4. Overview of cerebrospinal fluid (CSF) biomarkers in Alzheimer’s disease (AD). AD 
biomarkers in the CSF are considered to reflect core elements of disease pathology including 
amyloid accumulation, tau phosphorylation and formation of neurofibrillary tangles and 
neuronal damage and degeneration. AD biomarker profile includes decreased CSF Aβ42 and 





Structural brain changes, such as atrophy and variations in brain tissue characteristics, can be 
assessed by widely available computed tomography (CT) or magnetic resonance imaging 
(MRI). Brain atrophy is a macroscopic manifestation of degenerative brain changes, such as 
loss of dendrites and neurons in AD (89). First changes are usually observed in the entorhinal 
cortex, amygdala and hippocampus in MCI and early AD patients (90-92), followed by atrophy 
in temporal neocortex and neocortical association areas (93, 94). The AD-associated pattern of 
structural MRI changes is closely related to cognitive decline (95-97) and is considered as a 
marker of disease progression (60, 98). More recently, the biological heterogeneity of AD has 
been substantiated by structural neuroimaging studies that revealed distinct AD subtypes of 
brain atrophy such as typical AD, limbic-predominant, hippocampal sparing and minimal 
atrophy AD (99, 100).  
Functional imaging 
An abnormal local neuronal (synaptic) activity can be indirectly detected by [18F]FDG-PET, 
an imaging method that measures regional cerebral glucose metabolism (101). Sperling et al. 
proposed a biomarker model where decreased [18F]FDG uptake, particularly in temporoparietal 
regions, is a marker of synaptic dysfunction in patients on the AD continuum (Figure 3) (6) 
that has already been implemented in the clinical use (102). Reduced [18F]FDG uptake within 
these regions was shown to emerge before clinically evident cognitive impairment (103-105) 
and to be associated with clinical progression in MCI and AD patients (106-108). In memory 
clinic settings, [18F]FDG PET adds to the differential diagnosis of dementia (60, 109). A recent 
study, however, questioned the general notion of [18F]FDG-PET as an exclusive marker of 
neuronal activity since it has been shown that [18F]FDG PET signal is determined by the 
glucose uptake in astrocytes (110).  
Molecular imaging 
In vivo imaging and quantification of brain Aβ burden can be assessed by PET imaging with 
amyloid tracers such as [11C]-Pittsburgh compound-B, [18F]flutemetamol, [18F]florbetapir, 
[18F]florbetaben (111-115). Amyloid PET positivity in MCI patients is associated with an 
increased likelihood of cognitive decline and a progression to clinical diagnosis of AD 
dementia (112). Interestingly, approximately 30% of cognitively healthy elderly show amyloid 
positivity (116, 117), which places them in the preclinical stage of AD pathophysiological 
continuum according to the research criteria (6, 60). Recent advances in the development of 
tau PET ligands have provided an opportunity for in vivo imaging of tau pathology in the brain. 
Increased retention of tau tracers was found in AD patients compared to healthy elderly 
controls, and accumulating evidence suggests relationship between tau PET findings, 
neurodegeneration and cognition (118-121). Future studies will elucidate the role of in vivo 




1.3 NOVEL CANDIDATE MARKERS – FOCUS ON SYNAPSES 
Biomarkers that have a potential to detect alterations in synaptic function during the earliest 
stages of AD, before a significant neuronal loss has occurred, may be important for successful 
prevention and timely therapeutic intervention. There are several available imaging methods 
that can provide in vivo information on brain synaptic function. Resting-state and task-based 
functional MRI (fMRI) and [18F]FDG-PET have been shown to provide valuable anatomical 
information on synaptic and network abnormalities in AD, even though both of these 
modalities pick up hemodynamic and metabolic signals and hence detect indirect neuronal 
functioning (6, 122-124). A more direct in vivo imaging of synapses has been recently 
developed by employing synaptic vesicle glycoprotein 2A (SV2A) PET (125-127). This 
method may provide a unique opportunity to image brain synaptic density in living patients 
although several challenges, such as the development of optimal PET tracer and strength and 
consistency in the relationship between decreased SV2A expression and synaptic loss in AD, 
are yet to overcome (128). The closest non-invasive measures of synaptic (dys)function to date 
may be obtained by electroencephalography (EEG) and magnetoencephalography (MEG) 
since these complementary methods directly measure electric and magnetic fields, respectively, 
generated by brain synaptic activity (129).   
1.4 QUANTITATIVE ELECTROENCEPHALOGRAPHY (QEEG) 
Hans Berger, a German psychiatrist, was the first to record human EEG (130). His extensive 
research yielded the first detailed descriptions of many EEG features in healthy subjects as well 
as in patients with neurological disorders. Hans Berger considered EEG a “window into the 
brain” which was later substantiated by the widespread use of EEG in different research settings 
as well as routine clinical practice (129, 130).  
Human EEG is a non-invasive diagnostic method that captures direct and real-time functioning 
of brain synapses. EEG, recorded at the scalp, mainly reflects summated excitatory and 
inhibitory postsynaptic potentials of a large number of neurons in the cerebral cortex (131). 
Synchronous polarization and laminar arrangement of cortical pyramidal neurons, that are 
spatially aligned and perpendicular to the cortical surface, make them ideal generators of 
dipolar current flow that can be recorded by scalp EEG (Figure 5) (129, 131).  
Figure 5. Illustration of 
human EEG recording at 
the level of the scalp. EEG 
mainly reflects summated 
excitatory and inhibitory 
postsynaptic potentials of 
a large number of spatially 
aligned and synchronously 




Resting-state EEG recordings are subjected to visual analysis in routine clinical practice. It 
includes a description of EEG waveforms in the terms of frequency, amplitude, morphology, 
polarity, etc., and is important for assessing the age- and state- appropriate EEG patterns as 
well as distinctive neurophysiological phenomena (131, 132). However, the reliability of visual 
EEG assessment depends on the skills and experience of electroencephalographers as well as 
the unambiguity of changes of interest (131). In addition, some of the EEG characteristics 
cannot be observed by sole visual inspection. Quantitative EEG (qEEG) allows objective and 
reproducible analysis of EEG signals and is defined as “the mathematical processing of 
digitally recorded EEG in order to highlight specific waveform components, transform the 
EEG into a format or domain that elucidates relevant information, or associate numerical 
results with the EEG data for subsequent review or comparison.” (133). Therefore, qEEG 
unfolds complex EEG signal in time, frequency and space domain and provides objective 
information on frequency (or spectral) components, temporal dynamics, and topographic 
estimates of cortical activity (Figure 6) (129). 
 
Figure 6. Quantitative EEG analysis in frequency (FFT spectral analysis; blue square), time 
(EEG microstate analysis; green square) and space domains (LORETA = low resolution brain 
electromagnetic tomography analysis; purple square). Adapted with permission from 
Smailovic U, Jelic V. Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG 
Approach. Neurol Ther. 2019;8(Suppl 2):37-55. © 2019 The Authors. 
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1.4.1 Frequency domain analysis 
EEG is primarily characterized by its oscillatory nature (131). Hans Berger, the discoverer of 
EEG, was also the first to describe its spectral components (134-136). Fast Fourier transform 
(FFT) spectral analysis is a method that transforms raw and continuous EEG data into the 
frequency domain and therefore allows for the quantification of the amplitude and power of 
EEG oscillations, averaged through time, across pre-defined frequency bands (Figure 6) (129). 
The definition of frequency bands stemmed initially from visual assessment of physiologically 
and pathologically relevant phenomena in EEG signal but was later substantiated by 
mathematical approaches such as factor analysis (137, 138). EEG frequency spectrum is 
usually characterized by four major categories of interest: delta (0 – 4 Hz), theta (4 – 7 Hz), 
alpha (8 – 12 Hz) and beta (>13 Hz) frequency bands. Normal resting-state EEG of an awake 
adult is predominantly characterized by frequencies in alpha range, also named “posterior 
dominant rhythm”. Alpha rhythm is attenuated with eyes opening and other mental alerting 
activities (131, 132). In addition to the thalamus and thalamo-cortical connections as presumed 
“pacemakers” of cortical rhythmic activity, the horizontal intracortical connections are thought 
to be important for the generation and spread of alpha rhythms (131, 139, 140). Theta activity 
is typically seen in drowsiness and sleep with only a small amount present in normal awake 
adult recordings. Mammalian hippocampus and entorhinal cortex were found to be the main 
sources of theta activity (131). In addition, cholinergic deafferentation of the cortex results in 
increased slow wave (delta and theta) activity, which highlighted central cholinergic system as 
the modulator of EEG oscillations (131, 141). Frequencies in delta range are related to sleep 
and anesthesia and were found to originate from both thalamus and cortex since their 
appearance survives thalamectomy, as revealed by experimental studies (131). Beta rhythms 
are a normal EEG finding with dominance over the frontocentral regions, associated with 
wakefulness and rapid eye movement (REM) sleep (131). Even though a lot has been learned 
about EEG current sources since the first human recording made by Hans Berger, the exact 
generators and mechanism of cortical rhythmic activity picked up by EEG remains to be fully 
elucidated. 
Generalized EEG slowing, characterized by increase in slow frequency (delta and theta) and 
decrease in fast frequency (alpha and beta) amplitude and power, is a consistent finding in 
patients along the clinical AD continuum (Figure 7) (142-151). These changes seem to develop 
with a certain temporal pattern including early alterations in power in theta and beta bands, 
followed by a decrease in alpha and an increase in delta power (142-144, 152). Additionally, 
referred qEEG alterations were shown to correlate with the degree of cognitive impairment 
(144, 147, 150, 153), performance in specific cognitive domains including memory, attention 
and verbal deficits (151, 154) and to be predictive of loss of ability to carry out activities of 
daily living (155). Several studies have provided evidence that generalized EEG slowing is of 
intermediate magnitude in SCD and MCI patients compared to AD and healthy controls (144, 
151, 153, 156). Moreover, an increase in theta and a decrease in alpha power were shown to be 
predictive of future cognitive decline in MCI (153, 156) and amyloid positive SCD subjects 
(157).  
Global field power (GFP) has been introduced as a simplified qEEG measure of generalized 
EEG amplitude. It summarizes multichannel recordings to a single measure that corresponds 
to the root mean of the spectral amplitudes across all channels (129, 148). Increase in GFP theta 
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and delta together with decrease in GFP alpha were reported in AD patients compared to the 
healthy controls (148, 158) while decrease in GFP alpha and beta was described in AD 
compared to MCI patients (148). Moreover, decrease in GFP alpha was predictive of 
progression to AD in the MCI patients during 2 years follow-up (148).  
Figure 7. Comparative EEG power spectrum in a cognitively healthy subject, patient with a 
clinical diagnosis of subjective cognitive decline, mild cognitive impairment, and Alzheimer’s 
disease. The global field power (GFP) is increased in a gradient-like manner in delta and theta 
bands and decreased in alpha and beta bands with the more severe stage of cognitive 
impairment. 
AD is characterized by disturbances in brain structural and functional connectivity as a result 
of widespread neuronal and synaptic loss and dysfunction (159, 160). Growing evidence from 
neuropathological, neuroimaging and electrophysiological studies further support the 
hypothesis of AD as a “global disconnection syndrome” (161). EEG is a convenient technique 
for the investigation of brain functional connectivity since it provides direct information on the 
synchronous firing of a large number of cortical neurons with a uniquely high temporal 
resolution. EEG coherence is a measure of the stability of phase differences, or rather the 
common variance of spectral activity detected at two electrodes (129, 162). The most 
prominent decrease in EEG coherence was reported in alpha band which was also found to 
correlate with neurophysiological performance in AD patients (145, 146, 149, 163, 164). EEG 
coherence in the sensor space, however, poses several limitations. It is computed and mapped 
between channel pairs and its interpretation is influenced by volume conduction effect, i.e., 
coupling of activities at two electrode sites may represent a single process that affects both 
electrodes at the same time (129). 
Global field synchronization (GFS) has been introduced as a qEEG measure of relative phase 
synchrony of oscillating neuronal networks over all electrodes at a given frequency (165). It is 
computed using a principal component analysis (PCA) of the electrode positions in the sine-
cosine diagram (sine and cosine coefficients are the results of FFT of the EEG signal and are 
entered for each electrode into the diagram). GFS corresponds to the normalized difference 
between the two resulting eigenvalues of PCA and is therefore the measure of the cloud spread 
of entry points, i.e., electrode entries. It indicates the degree (percentage of EEG activity) that 
oscillates with a common phase over all electrodes at the investigated frequency (129, 165). 
Reduced GFS in alpha and beta and increased in delta frequency band has been reported in 
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patients with SCD, MCI and AD compared to the cognitively healthy controls (166). These 
GFS changes were additionally found to correlate with Mini-Mental State Examination 
(MMSE), Montreal Cognitive Assessment (MoCA) score and Clinical Dementia Rating scale 
(CDR) in AD (167, 168). Several other measures of EEG synchronization, including 
synchronization likelihood (SL) and phase lag index (PLI), were reported to decrease in alpha 
and beta bands in AD patients and to correlate with the disease severity (169-172). Overall, 
qEEG measures in the sensor space seem to consistently show decreased EEG synchronization 
in fast frequencies in AD. 
1.4.2 Time domain analysis 
“Is it possible to demonstrate the influence of intellectual work upon the human 
electroencephalogram, insofar as it has been reported here? Of course, one should not at first 
entertain too high hopes with regard to this, because mental work, as I explained elsewhere, 
adds only a small increment to the cortical work which is going on continuously and not only 
in the waking state.” 
    Hans Berger, 1929 (130, 173) 
EEG signal averaging, which has been conventionally performed in EEG analyses, extracts 
valuable information on EEG components from both resting-state and event-related EEG 
recordings. However, resting brain state is characterized by continuous and spontaneous mental 
activity that vigilantly changes in a sub-second time scale. This ongoing intrinsic brain activity 
demands considerably high energy consumption and is thought to be organized in distinctive 
functional networks (174, 175). EEG analysis in the time domain therefore provides a valuable 
tool for investigating the dynamics of large-scale brain networks with a millisecond time 
resolution (129, 175). Temporal organization of neuronal networks can be analyzed using 
topographies of electric fields, i.e., representation of voltages recorded at all electrodes on a 
single scalp map at a given moment in time. Previous studies using resting-state EEG 
recordings have shown that these topographies of electric fields remain stable for short periods 
before abruptly transitioning into the new topographic arrangement (Figure 6) (176). It was 
assumed that they may represent basic elements of brain information processing and were 
referred to as “atoms of thoughts” (177).  
Referred periods of the stable scalp electric potential topographies were named functional 
microstates. There are several computational approaches in microstate analysis, with 
commonly used modified k-means spatial cluster analysis that groups together similar 
topographies (at GFP peaks) and eventually determines the best-fitting maps that optimally 
explain the variance in the EEG data. Previous studies have shown that the mean duration of 
microstates is 60 to 150 ms (178, 179) which also coincides with the resolution of human 
information processing (180). Moreover, they have demonstrated that microstate topographies 
are remarkably consistent across EEGs of different subjects, only 4 distinct topographies 
(named map A, B, C and D) appear to be optimal to explain most of the human resting-state 
EEGs (Figure 8 and 9) (178, 179). Following these findings, numerous studies investigated 
differences in microstates topographies and parameters in association with age, medication, 
and different psychiatric and neurological conditions (179, 181, 182). Reduced microstates 
duration and anteriorization of the centers of gravity of the microstate topography were initially 
reported in AD patients compared to healthy controls (183-185). Conversely, two studies 
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employing more advanced methodological approaches, such as k-means spatial cluster 
analysis, reported no differences in microstate parameters nor topographies in AD patients 
compared to healthy controls, however, they involved a modest number of study participants 
(186, 187). A recent multi-centric study that involved over two hundred cognitively impaired 
patients reported increased duration, occurrence, and coverage of microstate map A in AD and 
MCI patients compared to healthy controls (188). Distinct organization and reproducibility of 
EEG microstate maps suggest them as a potential tool for detecting changes in the organization 
and activation of large-scale brain networks. 
 
 
Figure 8. Four representative EEG microstates named as maps (classes) A, B, C and D are 
highly consistent across independent studies. With permission from Michel CM, Koenig T. 
EEG microstates as a tool for studying the temporal dynamics of whole-brain neuronal 





Figure 9. Four representative EEG microstates named as maps (classes) A, B (asymmetric), C 
and D (symmetric) in 308 healthy elderly controls (age range: 60 – 93 years). Adapted with 
permission from Smailovic U, Koenig T, Laukka EJ, et al. EEG time signature in Alzheimer´s 
disease: Functional brain networks falling apart. Neuroimage Clin. 2019;24:102046. © 2019 
The Authors. Published by Elsevier Inc. 
1.4.3 Space domain analysis 
Direct interpretation of scalp electric field topographies in the context of activation of specific 
brain regions requires additional EEG source localization analysis. These methods involve 
EEG inverse solutions that estimate 3-dimensional (3D) distribution of neuronal activity that 
could generate EEG signal recorded at the level of the scalp. Inverse calculations do not provide 
a unique solution, however, they are constrained to the cortical grey matter and synchronous 
activation of large clusters of cortical neurons (129). One of the EEG source localization 
techniques is a low-resolution electromagnetic tomography (LORETA) which estimates and 
displays the 3D cortical sources of electric brain activity (Figure 6) (189). The performance of 
LORETA as an EEG imaging method has been previously validated through studies that 
combined LORETA and structural and functional MRI (190, 191) as well as [18F]FDG-PET 
imaging (Figure 10) (192). 
Several studies have employed LORETA to locate cortical sources of altered EEG activity in 
AD. These studies reported a reduction in alpha activity in parietal and occipital lobes as well 
as a widespread increase in delta and theta activity in AD patients compared to healthy controls 
(150, 193-196). Similar changes in resting-state EEG sources were also described in subjects 
with subjective cognitive complaints and MCI patients (197) and were reported to be sensitive 
to the disease progression (196). EEG measures of functional connectivity have also been 
employed in the source space where decreased lagged connectivity in the alpha band in the 
temporal and parietal cortex (195) as well as more widespread increase in lagged connectivity 
in theta and delta band were reported in AD patients (195, 198).  
1.4.4 qEEG in relation to AD biomarkers  
Disturbances in qEEG measures in frequency, time and space domain have been repeatedly 
reported in patients along the AD continuum, however, their relationship with AD 
neuropathology and other molecular, structural, and functional (synaptic) markers have not 
been extensively investigated. A previous study has reported a negative correlation between 
CSF Aβ42 levels and current source density in the right temporal lobe in the theta band and 
between t-tau levels and lagged phase synchronization between the left frontal eye field and 
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the right auditory area in alpha band in AD patients (199). Conversely, another small-scale 
study reported a negative correlation between EEG slowing and tau levels in patients with AD 
(158). The correlation between t-tau/Aβ42 ratio and EEG theta power was further revealed in 
cognitively healthy elderly subjects (200). A study that included a larger cohort consisting of 
over 300 healthy elderly with subjective memory complaints reported a lack of associations 
between global amyloid load, as assessed by amyloid PET, and PLI measure (201). The 
association between hippocampal and cortical gray matter volume and sources of resting-state 
EEG, as assessed by LORETA, was the most consistently reported in alpha frequency band in 
MCI and AD patients (202-205). 
The coupling between glucose metabolism and synaptic activity in the brain was further 
explored with [18F]FDG-PET and EEG studies. Association between regional glucose 
metabolism and localization of intracerebral EEG generators across distinct frequency bands 
was reported in both healthy controls and in patients with cognitive impairment (Figure 10) 
(192, 206, 207). Although both modalities are considered to reflect brain synaptic activity, 
[18F]FDG-PET assesses an indirect metabolic signal and involves the use of radioactive tracer. 
 
 
Figure 10. The correspondence between brain glucose metabolism determined by [18F]FDG-
PET and brain electric activity as estimated by EEG LORETA. The images show transaxial 
PET (left) and transaxial and sagittal EEG LORETA images (middle and right) of two subjects 
(top and bottom row). The more intense red color indicates higher metabolism/alpha band 
activity. With permission from Dierks T, Jelic V, Pascual-Marqui RD, et al. Spatial pattern of 
cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-
generators in Alzheimer's disease. Clin Neurophysiol. 2000;111(10):1817-1824. © 2000 
Elsevier Science Ireland Ltd. 
Several studies investigated the relationship between APOE ε4 genotype and AD-associated 
alterations in EEG measures. Increased slow EEG activity and reduced activity and coherence 
in alpha band were reported in APOE ε4 carriers with AD (146, 195, 208, 209). However, the 
referred relationship between APOE genotype and oscillatory brain activity was brought into 
question following a report from a larger-scale study that showed a more pronounced EEG 
slowing in AD patients that were APOE ε4 non-carriers (210). 
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EEG offers several methodological advantages; direct access to neuronal signaling, high time 
resolution, noninvasiveness, portability, low cost, and wide availability (129). However, the 
relationship between qEEG measures and biological processes associated with AD, especially 
in the early stages of the disease, requires further large-scale investigation before establishing 
the potential role of qEEG in the diagnostic workup of AD. 
1.5 CSF SYNAPTIC BIOMARKERS  
Synaptic proteins emerged as candidate markers for early AD due to their close relationship 
with the cognitive status and disease progression (34, 35, 211, 212). Several pre- and 
postsynaptic proteins were shown to be altered in the brains of AD patients, with a recent focus 
on neuron-specific protein neurogranin (213). Neurogranin is a post-synaptic protein mainly 
expressed by excitatory neurons of the cortex and hippocampus (214, 215). It has a crucial role 
in synaptic plasticity and LTP by regulating calmodulin availability in response to the increased 
intracellular calcium levels (216, 217). A reduction in neurogranin levels in the hippocampus 
and cortex was found in AD patients compared to cognitively healthy controls (211, 213). 
Referred findings motivated the investigation of neurogranin as a potential fluid-based marker 
of synaptic pathology in AD. Several studies have shown that CSF neurogranin concentration 
is increased in MCI and AD patients, predictive of cognitive deterioration and metabolic and 
structural AD-related biomarker changes (218, 219, 220). Increased leakage and/or secretion 
of neurogranin into the brain interstitial fluid and CSF as a result of AD-related neuropathology 
was proposed as a potential mechanism behind its alterations in the CSF (221), however, the 
exact relationship between changes in neurogranin levels in the CSF and brain tissue remains 
to be elucidated.  
In addition to neurogranin, several other CSF synaptic proteins are under investigation as 
potential novel markers of AD-related synaptic degeneration, including growth-associated 
protein-43 (GAP-43), synaptic vesicle protein 2A (SV2A), synaptosomal-associated protein 25 
(SNAP-25), and synaptotagmin (128, 222-225). 
1.6 TRANSLATIONAL POTENTIAL OF SYNAPTIC MARKERS 
The urgency to understand the pathophysiological processes of AD, develop novel and reliable 
biomarkers as well as to provide a platform for testing potential novel therapeutic agents has 
given a strong initiative to model the disease in animals (226, 227). Animal models of AD have 
proven to be of significant value for a thorough investigation of the isolated key elements of 
the disease (226). However, preclinical findings on pathophysiological mechanisms and 
neuropathological changes in AD often require brain tissue investigations and hence do not 
have direct translational value. In parallel use of biomarkers in preclinical and clinical research 
studies opens a possibility for a more straightforward translation of basic and clinical findings 
in the AD field. It includes discovery of novel disease markers and their relationship with 
neuropathological changes, selecting potential therapeutics and estimating preclinical and 
clinical drug efficacy (Figure 11). Early and reliable synaptic markers that closely reflect 
clinical symptoms and underlying pathology together with animal models that exhibit AD-
related synaptic degeneration may therefore represent an important step in bridging the 
translational gap between preclinical and clinical research fields. In this context, animal models 
of isolated pathological pathways of AD pose a certain advantage since they disentangle the 
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interplay of known (and yet unknown) causes of the disease. It complements investigations of 
novel synaptic biomarkers in the large and heterogeneous cohorts of patients along the AD 
continuum.  
 
Figure 11. The importance of in parallel use of biomarkers in preclinical and clinical AD 
research highlighted by the different (and common) investigations that can be performed in 
preclinical animal and clinical studies. 
1.7 ANIMAL MODELS OF ALZHEIMER’S DISEASE 
1.7.1 Overview of animal models 
Animal models of AD span from invertebrates such as roundworm (Caenorhabditis elegans) 
and fruit fly (Drosophila melanogaster) across vertebrates such as zebrafish and rodents, all 
the way to the nonhuman primates (226, 228). The size and reproduction characteristics of the 
rodents, in particular mouse (Mus musculus), made them one of the most widely used models 
in research (229). Meanwhile, the discovery of mutations in the APP and PSEN gene in familial 
AD provided crucial knowledge for generating animal models of the disease (226). The first 
transgenic mouse model of AD, named PDAPP, overexpressed human APP with the Indiana 
mutation which led to the 10-fold elevation of APP and development of amyloid plaques at 6 
to 9 months of age (230). Following the development of the referred model, various APP 
transgenic models with different fAD APP mutations and promotor combinations were 
developed. Some of the common models are Tg2576 and APP23 mice that overexpress human 
APP with the Swedish mutation that increases production of both Aβ40 and 42 (226, 231-233). 
Since then, several mutant presenilin models have been crossed with APP mice in order to 
produce double transgenic mice models, such as APP/PS1, that exhibit early and accelerated 
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amyloid deposition (234, 235). 5XFAD transgenic mouse model was further produced using 
five fAD mutations (three APP and two PSEN 1 mutations) and has shown to develop rapid 
and severe amyloid pathology and neuronal loss (236). Even though these models are valuable 
for the investigation of progressive amyloid pathology and its downstream effects, most of 
them do not develop typical signs of tau pathology, i.e., NFTs, and/or (severe) 
neurodegeneration. Consequently, animals that model tau pathology, by expressing mutant 
human microtubule-associated protein tau (MAPT), were developed. These mice exhibit 
extensive neurodegeneration, NFTs and cognitive impairment (54, 237). In order to 
recapitulate two pathological hallmarks of AD, triple Aβ-tau transgenic mice models were 
further introduced (238). However, multiple gene mutations pose an increased risk of artificial 
phenotypes and more importantly, mutant MAPT gene is found in frontotemporal dementia 
with parkinsonism linked to chromosome 17 (FTDP-17) and not in AD (239). Several non-
transgenic mouse models, including senescence-accelerated, seeding, neurotransmitter, and 
toxin-induced, were additionally developed in an attempt to model aspects of sAD pathology 
and cognitive impairment (226, 240). However, mouse models of AD often fail to mimic 
sufficiently well an interplay of different pathophysiological pathways found in human AD 
and/or they utilize multiple mutations found in familial forms of the disease. Nevertheless, they 
provide a valuable platform for in-depth investigation of main neuropathological components 
of the disease, temporal and spatial spread of pathology as well as their downstream effects.  
1.7.2 App knock-in mouse models of AD 
Transgenic mouse models of amyloid pathology in AD have dominated the field of preclinical 
animal research, however, they exhibit certain limitations in terms of APP overexpression-
related artifacts. Overproduction of APP fragments in these models, in addition to Aβ, induces 
artificial phenotypes that are hard to distinguish from the ones that develop due to sole Aβ 
accumulation (239). Additionally, different transgene constructs and promoters, lack of clear 
negative controls, use of certain mutations that are not present in AD, and high mortality 
exemplify further disadvantages of transgenic models (239). App knock-in mice have been 
introduced as models of AD that overproduce Aβ without the overexpression of APP and 
therefore bypass some of the shortcomings of the previous models (241). App knock-in mouse 
models harbor Swedish and Beyreuther/Iberian mutations (AppNL-F) while the AppNL-G-F mice 
additionally possess the Arctic mutation (241). The Swedish mutation facilitates β-secretase 
cleavage of APP and therefore increases the total amount of Aβ40 and Aβ42 (233, 242) while 
the Beyreuther/Iberian mutation affects γ-cleavage which results in increased Aβ42/Aβ40 ratio 
(243). The Arctic mutation additionally enhances the aggregation of Aβ peptides by promoting 
Aβ protofibrils formation (244). AppNL-F and AppNL-G-F mice develop amyloid plaques and 
memory impairment in an age-dependent manner (Figure 12) (241). AppNL-F mice exhibit initial 
Aβ deposition at 6 months and memory impairment at 18 months of age (241), even though a 
more recent study reported only modest cognitive deficits in this model (245). AppNL-G-F mice 
exhibit aggressive and early Aβ pathology with initial cortical and subcortical deposition at 2 
and 4 months, respectively, while memory impairment was observed by 6 months of age (241, 
246). Both of these models present with neuroinflammation characterized by accumulation of 
microglia and activated astrocytes around Aβ plaques (241). Even though App knock-in mice 
do not model the most common, sporadic form of AD nor exhibit neuronal loss or NFTs, they 
were shown to accumulate phosphorylated tau in dystrophic neuronal processes around Aβ 
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plaques (247). Besides the differences in the level and rate of induced pathologies (Figure 12), 
these two models present with several differences. AppNL-F mice lack subcortical Aβ deposition 
and, importantly, Aβ sequence in AppNL-F mice corresponds to the wild-type sequence since the 
arctic mutation in AppNL-G-F affects twenty-second amino acid of Aβ (244). Additionally, 
modest cognitive deficits reported in AppNL-F mice suggest them as a model of “preclinical 
AD”. On the other hand, AppNL-G-F mice may be useful models for investigating aggressive Aβ 
pathology and its downstream pathophysiological effects, more pronounced 
neuroinflammation and behavioral deficits. 
 
Figure 12. Aβ plaques in the cortex and hippocampus of 12 months old AppNL-F and AppNL-G-F 
mice. Brain sections stained for Aβ using mouse monoclonal OMAB antibody (Agrisera, AS10 
932). Lower right corners show Aβ plaques with higher magnification. Scale bars = 100 µm. 
Adapted from Smailovic U, Delac L, Liman V, et al. Translational potential of Alzheimer’s 
disease CSF biomarkers from man to mouse – CSF neurogranin correlates with tau and 
amyloid-β pathology in App knock-in mouse models. Manuscript in preparation. 
1.7.3 Synaptic pathology in App knock-in mouse models 
The initial publication that introduced App knock-in mice also described synaptic alterations in 
these animal models of AD. The changes included reduction of pre- and post-synaptic proteins, 
synaptophysin and postsynaptic density protein 95 (PSD-95), respectively, in the proximity of 
Aβ plaques (241). Additionally, loss of mushroom postsynaptic spines, as a result of 
extracellular Aβ42 accumulation, was demonstrated in the hippocampal neurons of AppNL-F 
mice (248). More recent studies reported impairment of synaptic function, including deficits in 
LTP in 3-4 months old AppNL-G-F mice  (249) as well as aberrant synaptic hyperactivity in the 
entorhinal cortex of AppNL-F mice present before the formation of amyloid plaques (250). 
Overall, AppNL-F and AppNL-G-F mice display pathology at the synaptic level, however, its 
influence on synaptic function and brain oscillatory activity in general remains to be 
investigated in more detail. Moreover, biomarker characterizations, such as the investigation 
of fluid biomarkers of synaptic degeneration and AD-associated pathology, may further 





2 SYDAD – PROJECT IN CONTEXT 
 
This project was part of the European Training Network (ETN) “Synaptic Dysfunction in 
Alzheimer Disease” (SyDAD) sponsored by Horizon 2020 Marie Sklodowska Curie Actions. 
SyDAD Training Network included 15 Early Stage Researchers (PhDs) in an international 
collaborative program with interdisciplinary training, translational approach stemming from 
both preclinical and clinical research conducted within academia as well as pharmaceutical 
companies, and mutual exchange programs between participating organizations. The main aim 
of the SyDAD Training Network was to elucidate pathophysiological pathways underlying 
synaptic dysfunction in AD and to identify potential pharmaceutical targets and novel 
biomarkers of the disease. Most of the PhD projects within the Training Network included 
preclinical investigations of different mechanisms behind synaptic pathology in AD, including 
the role of APP processing and Aβ, propagation of tau pathology, mitochondrial dysfunction, 
and cholesterol homeostasis. The aim of the present project was to bridge preclinical and 
clinical studies and investigate potential novel synaptic biomarkers in both animal models of 
AD and clinical cohorts of patients with different stages of cognitive impairment. The 
experimental part of the project, involving App knock-in mouse models, was partly performed 
as an exchange program (secondment) and extensive collaboration with University of 
Gothenburg (CSF analyses) and Janssen Pharmaceutica R&D1, Beerse, Belgium (EEG 










The present thesis aimed to provide new insights on markers of synaptic dysfunction and their 
relationship to Alzheimer’s disease pathology in both patients and animal models. The primary 
focus was on qEEG as a potential modality for detecting early functional (synaptic) deficits in 
AD. The specific aims for each study were as follows:   
In Paper I, to investigate the association between qEEG measures of global EEG power and 
synchronization and conventional CSF biomarkers of AD in a cohort of patients diagnosed 
with SCD, MCI and AD. 
In Paper II, to examine differences in EEG microstate topographies and parameters between 
healthy elderly and memory clinic patients and their relationship to conventional CSF markers 
of AD in patients diagnosed with SCD, MCI and AD. 
In Paper III, to investigate the correspondence between brain functional connectivity 
measured by means of topographical EEG analysis and regional glucose metabolism registered 
by [18F]FDG-PET in patients with MCI and AD and with biomarker-verified AD molecular 
pathology. 
In Paper IV, to investigate the association of CSF synaptic marker neurogranin with qEEG 
measures as well as their potential to predict clinical progression to AD in MCI patients. 
In Paper V, to assess the translational potential of CSF neurogranin and its relationship to AD 
pathology (Aβ and tau) in App knock-in mouse models. 
In preliminary experimental study presented in the method section of the thesis, to 
investigate changes in EEG power spectrum in relation to the accumulating Aβ pathology in 





4.1 ETHICAL CONSIDERATIONS 
All studies were performed in accordance with the ethical standards of the national and 
institutional research committees and Declaration of Helsinki. Study I and II were approved by 
regional ethics committees in Stockholm and Uppsala, Sweden. The use of SNAC-K data was 
additionally authorized by written approval from the responsible person and data manager for 
SNAC-K population study. Study III and IV were approved by regional ethics committees in 
Stockholm and Lund, Sweden. Study V was approved by Linköping’s animal experiment 
ethical committee, Sweden. Preliminary data presented in the thesis was conducted in 
collaboration with Janssen Research & Development, Belgium, while all animal experiments 
were performed in strict accordance with the guidelines of the Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) and with the European 
Council Directive of 24 November 1986 (86/609/EEC) and European Ethics Committee 
directive (2010/63/EU) for the protection of laboratory animals. In line with Belgian 
governmental directives, all protocols were approved by the Animal Care and Use Committee 
of Janssen Pharmaceutica NV. 
4.2 PARTICIPANTS 
A general overview of the study participants (Study I – IV) involved in the present thesis is 
presented in Table 1.  
4.2.1 Study I and II 
The patient population in study I and II included patients recruited at the Memory Clinic, 
Karolinska University Hospital-Huddinge, Sweden. The study cohort consisted of 637 patients 
clinically diagnosed with SCD (n = 210), MCI (n = 230) and AD (n = 197) according to the 
Jessen et al. 2014, Winblad et al. 2004, and ICD-10 criteria (5, 7, 12). All patients underwent 
standard assessment consisting of general clinical and neurological examination, 
neuropsychological testing, brain imaging with MRI or CT, screening blood tests, CSF 
sampling and conventional biomarker analysis and resting-state EEG recording.  
Study II additionally included healthy elderly controls that were part of the SNAC-K 
population-based study and that resided in Kungsholmen district, Stockholm. SNAC-K study 
recruited healthy elderly individuals above 60 years of age that have been followed-up over 
time. The study participants underwent comprehensive baseline assessment including 
neuropsychological test battery and general clinical and neurological examination, MRI 
imaging and resting-state EEG recordings. A total number of 308 out of 484 participants with 
EEG recordings were included in the study II. The exclusion criteria were:  
− MMSE score lower than 27 points 
− decline in MMSE > 2 points during any of the follow-ups (6 years) 
− dementia diagnosis during any of the follow-ups (6 years) 
− presence of any major neurological or psychiatric disorder. 
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More information about SNAC-K cohort can be found on the SNAC-K population study 
webpage: https://www.snac-k.se/.  
4.2.2 Study III 
Study III included a subsample of patients recruited at Karolinska University Hospital-
Huddinge, Sweden that were clinically diagnosed with MCI (n = 41) and AD (n = 26) and that 
underwent [18F]FDG-PET imaging and EEG recordings in addition to the standard clinical 
assessment. The study was conducted in two parts, the first part involved the whole cohort of 
MCI and AD patients and the second part involved a subsample of patients that were CSF 
amyloid positive. For the second part, only patients that had available CSF sample from the 
biobank were selected (24 MCI and 18 AD) and stratified into amyloid positive according to 
the CSF Aβ42/40 ratio status, with the cut-off for amyloid positivity CSF Aβ42/40 ratio < 0.89. 
In comparison to CSF Aβ42, Aβ42/40 ratio was shown to compensate for inter-individual 
differences in the total Aβ production and to have superior diagnostic performance (251, 252). 
The second part of the analysis therefore included 14 amyloid positive MCI (or “MCI due to 
AD”) and 18 amyloid positive AD patients. 
4.2.3 Study IV 
Study IV included 99 patients recruited at Karolinska University Hospital-Huddinge, Sweden 
that were clinically diagnosed with MCI. All patients underwent standard assessment as 
described above for studies I and II. A subsample of MCI patients has been followed-up over 
time (n = 72) and stratified into stable MCI (n = 41) and progressive MCI (n = 31) according 
to the clinical progression to AD dementia during 2-years follow-up. Stable and progressive 
MCI patients were further stratified into CSF amyloid positive (12/41 of patients in stable and 
19/31 of patients in progressive MCI group) according to the cut-off for CSF Aβ42 positivity 
< 550 ng/L (Laboratory at Karolinska University Hospital Huddinge). Clinically available CSF 
Aβ42 value was used for the stratification since insufficient number of patients had available 
























































































































































































































































































































































































































































































































































































































































































































































































































































































4.3 ANIMAL MODELS 
4.3.1 Study V  
Experimental preclinical studies in the present thesis were conducted on two App knock-in 
mouse models of AD that harbor double (Swedish and Beyreuther/Iberian mutations; AppNL-F 
mice) and triple mutations (additional Arctic mutation, AppNL-G-F mice). In general, these 
mouse models overproduce Aβ and exhibit enhanced Aβ protofibril formation. Study V 
investigated AD biomarkers in the CSF of 12 months old AppNL-F, AppNL-G-F, and wild type 
controls (Appwt/wt). It was conducted on a total of 25 animals, including heterozygous and 
homozygous App knock-in mice: 8 Appwt/wt, 5 Appwt/NL-F, 5 AppNL-F/NL-F, 2 Appwt/NL-G-F and 5 
AppNL-G-F/NL-G-F mice. Both male and female mice were used. 
4.3.2 Preliminary study 
Preliminary/unpublished study presented in the thesis introduces longitudinal in vivo EEG 
recordings on App knock-in mice and age-matched wild type controls. The experiments 
involved both male and female homozygous AppNL-F (n = 29), AppNL-G-F (n = 20) and age-
matched Appwt mice (n = 40). All animals underwent surgical electrode implantation at 10 
weeks of age with baseline EEG recording at 12 weeks of age and four subsequent longitudinal 
recordings performed at three (for AppNL-G-F) or six/twelve weeks (for AppNL-F) interval. For 
AppNL-F it included recordings at 12, 18, 24, 36 and 48 weeks, while for AppNL-G-F at 12, 15, 18, 
21 and 24 weeks of age (Figure 13). All mice were single housed in a soundproof holding room 
with continuously controlled temperature, humidity, and 12h light/dark cycle regime (lights on 
07:00 – 19:00 hours, light intensity: ~ 100 lux) and tap water and food (SAFE diet A05) 
available ad libitum. 
 
Figure 13. Experimental design of the study involving in-vivo EEG recordings in two App 
knock-in mouse models of AD. The study included AppNL-F, AppNL-G-F, and age-matched Appwt 
mice that underwent surgical electrode implantation and longitudinal EEG recordings at five 
different time points with respect to the pathology progression. Model characteristics that 
typically develop in an age-dependent manner in AppNL-F and AppNL-G-F mice are outlined in 
the yellow sections underneath the time axis. 
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4.4 METHODS – CLINICAL STUDIES 
4.4.1 qEEG analysis  
EEG recording setup and preprocessing 
All EEGs from the patient population were recorded on the Nervus System at the Department 
of Clinical Neurophysiology, Karolinska University Hospital-Huddinge. The electrode 
placement followed the standard 10/20 international system, including 19 scalp, two earlobe 
and two electrooculogram (EOG) electrodes, which made the recording procedure comparable 
to the standard setups used at the international clinical and research sites. In addition, this 
number and electrode placement was shown to be adequate to record and analyze 
characteristics of brain electric activity (132). All EEGs were recorded during awake resting-
state which poses certain advantages when it comes to the neurophysiological studies, such as 
its common use in the clinical setting, straightforward implementation in both research and 
clinical investigations, minimal requirements for the patient engagement and less variation 
compared to the task- and stimuli- EEG paradigms. Patients’ vigilance states were closely 
monitored during the whole recordings by medical technicians. Electrode impedances were 
below 5 kΩ and EEGs were sampled at a rate of 256 Hz with band-pass filters between 0.5 Hz 
and 70 Hz. All EEG recordings were exported in average reference montage.  
Resting-state EEG recordings of the healthy elderly from SNAC-K database were recorded on 
the Schwarzer EEG Natus Incorporated System by using Easy Caps. The electrode placement 
and recording setup corresponded to the procedure performed in the patient population, as 
outlined above.  
All EEG recordings (patient population and healthy elderly) were preprocessed in Brain Vision 
Analyzer, version 2.0 software (Gilching, Germany) with the following procedure: 
− semiautomatic independent component analysis (ICA) algorithm for the removal of 
ocular, blink and electrocardiographic artifacts 
− visual inspection and manual rejection of the remaining artifacts, episodes of 
drowsiness and other non-resting-state vigilance states 
Frequency domain analysis 
QEEG analysis in the frequency domain (Figure 6) was conducted in study I and IV. This type 
of investigation was selected for several reasons. First, it is the most common form of qEEG 
analysis that provides measures of power and synchronization of EEG oscillations across 
different frequency bands that bear physiological significance. Second, measures of EEG 
power and synchronization were shown to capture changes in brain oscillatory activity in 
cognitively impaired patients (253). Third, these measures have straightforward computation 
in user-friendly software which suggests them as candidates for broad research and clinical 
implementation. In particular, measures of global field power (GFP) and synchronization 
(GFS) were employed in study I and IV. GFP and GFS have been previously investigated in 
well-characterized memory clinic cohorts (148, 166), study with longitudinal design (148) and 
in several correlative studies involving CSF markers and measures of symptoms severity (158, 
167, 168). Both GFP and GFS recapitulate multichannel EEG data in a single measure of global 
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EEG power and synchronization which makes them appealing candidates for investigations of 
their relationship with other biological markers. Even though conventional FFT power spectra 
analysis provides more detailed results (one parameter per derivation), the advantage of global 
EEG measures is that they consider all electrodes equally and avoid problems of multiple 
testing and a priori selection of derivations for further correlative analyses. Both GFP and GFS 
were analyzed in four conventional frequency bands: delta (1 – 3.5 Hz), theta (4 – 7.5 Hz), 
alpha (8 – 11.5 Hz) and beta (12 – 19.5 Hz).   
Time domain analysis 
Quantitative EEG analysis in the time domain (Figure 6) was conducted in study II. EEG 
microstate analysis can be used to investigate the temporal organization of large-scale brain 
networks with a high time resolution. Microstate maps represent voltages recorded at all 
electrode sites on a single scalp map in one moment in time. Four distinct microstate maps have 
been shown to be sufficient to explain around 60-80% of the total variance of the human EEG 
data (Figure 9) (179). In addition, previous studies have shown that these four maps are highly 
reproducible across different clinical cohorts, including patients with cognitive impairment 
(179, 186, 187). These characteristics made them appealing for studying dysfunction of resting-
state networks in patients along AD continuum. Microstate topographies last for a certain 
period (60 – 150 ms) and do not overlap in time. Therefore, 19 channel EEG recording can be 
visualized as a time-series of microstate maps that alternate through time.  
Steps of microstate analysis conducted in study II are outlined in Figure 14. Microstate maps 
can be evaluated in terms of the change in their topographies and parameters. Microstate 
parameters refer to the duration, occurrence (time per second) and contribution (expressed as 
percentage of the time that each map occupies). Microstate maps were selected at GFP peaks 
throughout the whole preprocessed EEG recording and subjected to the modified k-means 
spatial cluster algorithm since microstate maps tend to change their topographies during low 
GFP values (Figure 14). The number of clusters was set to the four most representative maps 
to be comparable to the previous studies and between patients and healthy subjects in study II. 
Cluster analysis yielded four most representative maps per subject (both healthy and patients) 
that were further averaged across all healthy elderly controls. These four grand mean microstate 
maps of healthy control group were classified as A, B, C and D based on their spatial similarity 
to the normative microstate maps as published previously (178). Next, individual microstate 
maps from both patient and healthy groups were assigned as maps A, B, C or D based on the 
spatial similarity to the controls’ grand mean maps (Figure 14). This sorting procedure was 
selected for several reasons. First, in order to compare the topographies of individual microstate 
maps between patients and healthy elderly controls, one would need to assign the maps to one 
of the microstate classes based on their spatial similarity. Second, this procedure was selected 
after visual inspection of the quality of several different sorting approaches to the individual 
microstate classification. These included sorting and assigning maps based on the grand mean 
maps of both healthy elderly and patient groups, separate sorting of patient and healthy groups 
based on their respective grand mean maps and sorting and assigning of the both patient and 
healthy groups based on the normative microstate maps from Koenig et al., 2002 (178). Visual 
inspection revealed that sorting based on the grand mean maps from the healthy elderly controls 
yielded the most consistent results, especially in the patient groups. This may be due to the use 
of the maps from the healthy elderly subjects for the correct classification of the patients’ maps  
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Figure 14. Steps of EEG microstate analysis: computation, sorting and assigning procedure in 
study II. With permission from Smailovic U, Koenig T, Laukka EJ, et al. EEG time signature 
in Alzheimer´s disease: Functional brain networks falling apart. Neuroimage Clin. 
2019;24:102046. © 2019 The Authors. Published by Elsevier Inc. 
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compared to the use of normative data that included a substantial number of younger subjects. 
Finally, the healthy elderly microstate maps presented in study II stem from a cohort that has 
been extensively evaluated and characterized and could therefore serve as normative data for 
future investigations of the microstate alterations in elderly and cognitively impaired patients. 
The hypothesis of study II was that microstate maps of healthy elderly and patients with 
cognitive impairment differ in their topographies, implying that map A of the patient with MCI 
or AD diagnosis could substantially differ from the topography of map A of the healthy elderly 
subject. For this reason, microstate parameters were analyzed by back-fitting healthy controls’ 
grand mean maps to the original EEG data of the patient groups. This approach yielded 
microstate parameters (duration, occurrence, contribution) of healthy elderly maps in the EEG 
data of patients with SCD, MCI and AD (Figure 14).   
Space domain analysis 
Space domain analysis in study III was performed using a specific solution to the EEG inverse 
(or source imaging) problem named LORETA (low resolution electromagnetic tomography). 
This particular type of analysis was selected for correlative [18F]FDG-PET – qEEG study since 
LORETA can provide topographical estimates of cortical electric activity based on the scalp 
EEG recordings (254). In study III, current sources estimated by LORETA were averaged 
across voxels in the five regions of interest (ROIs) bilaterally: frontal, parietal, temporal, 
occipital and limbic lobes. The selection of ROIs was matched to the corresponding PET ROIs. 
Correlation of LORETA estimates of current source densities has been previously related to 
cortical brain glucose metabolism in patients with AD (192, 207). Study III further investigated 
the relationship between cortical glucose metabolism and topographical EEG measures of brain 
functional connectivity in MCI and AD patients with and without biomarker evidence of AD 
pathology. EEG analysis of brain functional connectivity included measures of instantaneous 
and lagged linear connectivity. Previous EEG studies have mostly employed measures of 
lagged functional connectivity in the inverse solutions due to the volume conduction effect, i.e. 
instantaneous spread of the electric fields through the biological tissue that confounds EEG 
measures of instantaneous connectivity. However, instantaneous synchronization of neuronal 
activity has physiological significance and may complement the investigation of functional 
disconnection due to AD. Both instantaneous and lagged linear connectivity measures were 
computed for each main brain lobe and all the remaining ROIs (brain lobes) yielding the 
measures of average connectivity between the respective main lobe and remaining cortex. The 
analysis focused on temporoparietal lobes for the correlative [18F]FDG-PET study. LORETA 
measures of functional connectivity were computed for each conventional frequency band. 
4.4.2 CSF biomarkers analysis 
CSF was obtained by lumbar puncture according to the standard procedure and as part of the 
routine clinical assessment. All samples were analyzed at Clinical Neurochemistry Laboratory, 
Mölndal, Sweden. The local cut-offs for conventional CSF biomarkers were as follows: Aβ42 
> 550 ng/L, t-tau < 400 ng/L and p-tau < 80 ng/mL (study I, II and IV) and CSF Aβ42/40 ratio 
> 0.89 (used for stratification of patients into CSF amyloid positive and negative in study III). 
In study IV, neurogranin was additionally analyzed on frozen CSF samples, kept at -80 °C and 
obtained from the biobank, using an in-house-developed ELISA protocol (213). 
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4.4.3 [18F]FDG-PET analysis 
Patients in study III underwent metabolic [18F]FDG-PET imaging at the Medical Radiation 
Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, 
Stockholm, Sweden. [18F]FDG-PET imaging was performed on a Siemens Biograph mCT 
scanner and preprocessed using Syngo.via program. Following the automatic template-based 
spatial normalization, mean [18F]FDG standardized uptake values ([18F]FDG-SUV) were 
calculated for bilateral five main brain lobes: frontal, parietal, temporal, occipital and limbic 
lobes as published in automated anatomical labeling atlas by Tzourio-Mazoyer et al. (255). In 
order to reduce interindividual variability, absolute [18F]FDG-SUV were normalized to the 
[18F]FDG-SUV in the cerebellum yielding [18F]FDG-SUV ratios (SUVR). Cerebellum was 
selected as a reference region since the sensitivity of cerebellar normalization in detecting AD-
related metabolic abnormalities has been previously validated in [18F]FDG-PET studies (256). 
The [18F]FDG-SUVR parietal and temporal lobes were selected for further correlative analysis 
with EEG LORETA measures due to their pronounced vulnerability and early involvement in 
AD.   
4.4.4 Statistical analysis 
Different statistical methods were used in the present thesis based on the study aim, hypothesis, 
and type of data available for analysis. Description of statistical analyses is reported in detail 
in respective papers.  
Multiple linear regression analysis 
Multiple linear regression models were employed in studies I and IV to investigate the 
relationship between CSF biomarkers and qEEG measures of global power and 
synchronization. In study I, conventional CSF biomarkers of AD (Aβ42, t-tau and p-tau) were 
used as independent and GFP and GFS in four conventional frequency bands as dependent 
continuous variables, while accounting for age, sex and MMSE in the whole group of memory 
clinic patients diagnosed with SCD, MCI and AD. More specifically, the analysis was 
controlled for MMSE to exclude group differences in qEEG measures that were present 
between patients due to the different severity of cognitive impairment. MMSE was selected as 
a more objective controlling variable compared to the group diagnosis. The same regression 
analyses were additionally performed in the separate diagnostic groups while controlling for 
age and sex. In study IV, multiple linear regression analysis was employed to investigate the 
relationship between CSF neurogranin (independent variable) and qEEG measures GFP and 
GFS (dependent variable) in MCI patients. The first model was controlled for age and sex while 
the second model was additionally controlled for CSF t-tau/Aβ42 ratio since both of these CSF 
measures correlate with CSF neurogranin and qEEG measures, as reported in the literature. 
The regression analyses were additionally performed in separate groups: stable, progressive, 
amyloid negative and positive MCI groups.   
Randomization statistics 
Multichannel scalp field EEG data can be analyzed using randomization statistics since they 
do not require many assumptions or data manipulations while providing a robust and 
physiologically meaningful interpretation of the data analysis. Basic principles of 
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randomization statistics and their implementation for EEG analysis in Ragu software have been 
provided in detail in Michel, 2009 (129), and Koenig et al., 2011 (257). In brief, randomization 
statistics test whether differences in EEG scalp field data occur by chance, i.e. due to random 
variance across the groups, by random shuffling the scalp field data across the subjects and 
groups, and then recomputing and comparing the differences (effect sizes) that stem from the 
real data against the data obtained by randomization (and then repeating this procedure multiple 
times). In study II, differences in microstate topographies between healthy controls and patient 
groups were assessed by non-parametric randomization topographic analysis of variance 
(TANOVA). TANOVA compares map differences between conditions. Topographic analysis 
of covariance (TANCOVA) was used to investigate the association between CSF biomarkers 
and changes in topography of different microstate maps since the predictors were continuous 
variables (CSF Aβ42, p- and t-tau). Age and sex were regressed out of the microstate data prior 
to the analyses. Both TANOVA and TANCOVA were conducted with 5000 randomization 
runs and a level of significance p < 0.05 (257). 
Correlations 
In study III, the associations between brain glucose metabolism and EEG LORETA measures 
of instantaneous and lagged linear connectivity in temporal and parietal lobes were investigated 
using Spearman’s rank correlation tests due to the non-normal distribution of the data. The 
analysis was exploratory, so the findings were presented with both corrected and uncorrected 
p-values. Correction for multiple comparisons was performed using Benjamini-Hochberg 
correction with 5% false discovery rate (FDR) since it adjusts p-values according to their 
ranking and minimizes false negatives reports. 
The association between conventional CSF biomarkers and EEG microstate parameters (study 
II) and between CSF neurogranin and conventional markers (study IV) were also investigated 
by means of Spearman's rank correlation coefficients. 
Logistic regression analysis 
In study IV, the potential of CSF neurogranin and qEEG measures to predict clinical 
progression to AD dementia in patients diagnosed with MCI was investigated by logistic 
regression analysis, adjusted for age, sex and MMSE. Classification accuracy of correctly 
categorized progressive and stable MCI patients was used to explore the predictive potential of 
CSF neurogranin and qEEG measures. The dependence of significant predictors (CSF 





4.5 METHODS – PRECLINICAL STUDIES 
4.5.1 CSF biomarkers analysis 
CSF sampling 
In study V, CSF samples were collected from cisterna magna by penetrating dura mater with a 
glass capillary while the mice were anesthetized. Collection under the dissection microscope 
allowed for the inspection of any blood contamination that may affect the results (Figure 15). 
All mice underwent the same procedure and the amount of collected CSF sample ranged from 
5 to 20 µl per mouse. 
 
Figure 15. Mouse CSF was collected by surgical procedure performed under the dissection 
microscope. The visualization of the cisterna magna and a large blood vessel that was avoided 
during CSF sampling is presented on the right.  
CSF analysis 
All mouse CSF samples were analyzed at Neurochemistry Laboratory, Mölndal, Sweden. Due 
to the limited amount of available CSF samples, a new ultra-sensitive assay named single 
molecule array (Simoa), which allows for the detection of proteins at very low levels, was used 
for the analyses. Simoa assay for mouse neurogranin analysis was recently developed, 
validated on both mouse and human CSF, and described in detail in Höglund et al., 2020 (258). 
Mouse CSF Aβ42 and tau were analyzed using Simoa HD-1 commercially available human 
and mouse kits, respectively.  
4.5.2 Brain tissue analysis 
Mouse brain tissue was divided into right and left hemispheres and dissected into hippocampus 
and cortex (right hemisphere) and dehydrated and embedded in paraffin (left hemisphere). The 
same Simoa assays, as used for the CSF analyses, were used to investigate neurogranin and tau 
levels in the mouse cortical and hippocampal lysates. The protein concentrations were 
normalized with the total protein concentrations analyzed in the respective brain lysates. For 
the purpose of study V, sections of paraffin-embedded left hemisphere were used for 
establishing immunohistochemical (IHC) staining protocol for the in-house developed anti-Ng 
antibody (Ng2) that was used in the Simoa assay. IHC staining was then used to investigate 
difference in neurogranin expression in App knock-in mouse models compared to age-matched 
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wild-type controls. Double neurogranin – Aβ IHC staining was further performed to investigate 
relationship between neurogranin expression and amyloid pathology in App knock-in mice. 
4.5.3 EEG recordings and analysis 
All mice underwent surgical implantation of surface screw electrodes at 10 weeks of age. 
Before surgery, animals were subcutaneously injected with 0.025 mg/kg analgesic Piritramide 
(Dipidolor). The whole surgical procedure was performed under deep isoflurane anesthesia 
(5% induction and 2% maintenance) while a heating pad was used to control animal body 
temperature. The animal was placed in the stereotactic frame instrument (Robot Stereotaxic, 
Neurostar, Germany) with the isoflurane anesthesia delivered via an inhalation mask. At the 
surgery site, an additional local spray analgesic was applied (Xylocaine, 10%). The head was 
shaved, and a sagittal incision was made to expose the skull. Holes were drilled for the 
placement of three depth needle recording electrodes (right hemisphere) and three surface 
(epidural) screw recording electrodes (left hemisphere). Three epidural electrodes were 
stereotaxically implanted in the left hemisphere at the following anterior-posterior (AP), 
medial-lateral (ML), dorsal-ventral (DV) coordinates relative to the bregma: Frontal left (FL) 
at AP +1.94 mm, ML -1.5 mm, Parietal left (PL) at AP -1.7 mm, ML -1.5 mm, Occipital left 
(OL) at AP -2.8 mm, ML -3.2 mm. Depth electrodes were inserted into the right hemisphere 
as follows: frontal cortex (Frontal right AP +1.94 mm, ML +1.5 mm, DV -1.2 mm), dorsal 
CA1 region of hippocampus (dCA1 right AP -1.7 mm, ML +1.5 mm, DV -1.7 mm) and ventral 
CA1 region of hippocampus (vCA1 right AP -3.16 mm, ML +3.0 mm, DV -3.6 mm). 
Reference electrode was placed 0.5 mm posterior and to the right of bregma (AP -0.5 mm, ML 
+0.5 mm) and ground electrode was placed in the midline above cerebellum (Figure 16; all 
coordinates according to the atlas by Paxinos and Franklin, 2012 (259)). Electrodes were 
connected to a pin (Future Electronics: 0672-2-15-15-30-27-10-0) with a small insert (track 
pins; DataFlex: TRP-1558-0000) and then inserted into a 10-hole connector, which was 
carefully fixed to the skull using dental cement. The wound was sutured, and mice were closely 
monitored during two-week recovery. 
 
Figure 16. Surgical placement of the three surface (epidural) screw electrodes in the left 
hemisphere above frontal (FL), parietal (PL) and occipital (OL) left cortex, and three depth 
electrodes in the frontal cortex (FR), dorsal CA1 (dCA1) and ventral CA1 (vCA1) region of the 
hippocampus in the right hemisphere. The position of Reference (Ref) and Ground electrodes 
are shown in black. 
 
 35 
After surgery, the animals received 0.3 ml analgesic subcutaneously (Carprofen, Rimadyl, 50 
mg/ml, Pfizer Ltd, UK diluted 1:10) and local analgesic on the wounds (Lidocaine spray 
Xylocaine, 1% solution, Astra Pharmaceuticals Ltd, UK). Animals were next individually 
placed in their home cage and kept in a heating box set at 26 C ± 2 C to avoid hypothermia 
with the temperature steadily decreasing over days until it reached room temperature. After 
two weeks recovery, the animals were habituated to the recording setup for 24 hours prior to 
the recording of the spontaneous EEG and locomotor activity for another 20 hours (10 h of 
light and dark phases). Recordings were taken in the animal’s home cages placed in the 
environmentally controlled, sound-attenuated Faraday cages. Locomotor activity of the 
animals was measured by two passive infrared (PIR) detectors located above every recording 
cage. Motion levels were analyzed from both PIR detectors. A notch finite impulse response 
(FIR) filter (50 Hz) was used to filter out possible noise caused by the main power line 
interference. EEGs were recorded at a sampling rate of 512 Hz with BioSemi ActiveTwo 
system (BioSemi, Amsterdam, Netherlands) and digitized with a resolution of 24 bits. All 
animals were single caged and allowed to move freely during recordings. The recording setup 
followed the same procedure at all recording timepoints. 
The vigilance states of the animals during each recording were assessed as active wakefulness 
(AW), quiet wakefulness (QW), non-rapid eye movement sleep (NREM) or rapid-eye 
movement sleep (REM) on the basis of EEG recording and locomotor activity of the animal 
according to the pre-defined criteria (Table 2 conform e.g., Ahnaou et al. 2009 (260)) and 
analyzed using a machine-learning Scoretool on 4 s artifact-free epochs. Examples of mice 
EEG recordings during different vigilance states of the animal are given in Figure 17. For the 
purpose of developing a machine-learning algorithm for the scoring of the vigilance states of 
the longitudinal 20 hours recordings, 20% of all available, AppNL-F,  AppNL-G-F and Appwt 
recordings at different time points were randomly selected for visual inspection and manual 
scoring of animals’ vigilance states according to the criteria outlined above. Following this 
procedure, automated machine-learning scoring tool was uniformly applied on all available 
EEG recordings. Next, difference in the duration spent in different vigilance states was 
calculated during both the dark and light phases of the total recording time (20 hours). 
EEG power spectra will be calculated in consecutive artifact-free 4 s epochs of QW state of the 
animals during the first 5 hours of dark period of EEG recordings. QW state and the first half 
of dark period were selected due to the closest relationship to the resting-state EEG and timing 
of clinical recordings in humans (mice are nocturnal animals and spend more time in sleep-
states during the light phase). To further facilitate the translational approach of the present 
study, recordings from the three surface (epidural) electrodes will be used for the subsequent 
analysis. EEG power spectra will be computed using FFT analysis and calculated as relative 




Table 2. EEG and locomotor characteristics of different vigilance states of the mouse. 
AW = active wake state, QW = quiet wake state, NREM = non-rapid eye movement sleep, 
REM = rapid-eye movement sleep. 
Figure 17. Example of different vigilance states and transitions between vigilance states of the 
mouse based on EEG, depth electrode recordings and locomotor activity (LMA). The difference 
in AW versus QW state is mainly based on LMA activity. Recordings presented from the 
following electrodes: FL = surface frontal left electrode; dCA1 = depth electrode in dorsal 
right CA1 region; vCA1 = depth electrode in ventral right CA1 region. Vigilance states defined 
as AW = active wake; QW = quiet wake; NREM = non-rapid eye movement sleep; REM = 
rapid-eye movement sleep. 
Vigilance 
state 
EEG and locomotor characteristics 
AW Low EEG amplitude, high and variable locomotor activity 
QW Low EEG amplitude, low or no locomotor activity 
NREM High amplitude slow-wave EEG activity, no locomotor activity 
REM Regular theta oscillations, no locomotor activity 
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4.5.4 Statistical analysis 
The data in study V was analyzed using non-parametric tests (Kruskal-Wallis test and 
Spearman rank correlation tests) due to the small sample sizes that prevented a more thorough 
investigation of the data distribution. Even though the experiments were conducted in line with 
the common practice in neuroscience and the 3Rs (replace, reduce, refine), small sample sizes 




5 MAIN FINDINGS AND THESIS SUMMARY 
The following section describes the main findings of the studies included in this thesis. More 
detailed results together with reflections and discussion are reported in the respective 
publications/manuscripts.  
5.1 PAPER I – ASSOCIATION BETWEEN QEEG AND CSF BIOMARKERS OF 
AD 
The main aim of study I was to investigate the association between qEEG measures of global 
power (GFP) and synchronization (GFS) and conventional CSF biomarkers of AD. The 
relationship between CSF markers and qEEG measures was investigated in the whole cohort 
of SCD, MCI and AD patients and subsequently in separate diagnostic groups. In the whole 
memory clinic cohort, CSF Aβ42 levels were significantly negatively associated with GFP in 
delta and theta frequency bands. CSF p- and t-tau levels were significantly negatively 
associated with GFP in alpha and beta frequency bands. Results indicated that lower CSF Aβ42 
levels are associated with increased EEG power in slow frequencies while higher CSF p- and 
t-tau levels correlate with decreased power in fast frequencies (Table 3). 
Multiple linear regression analysis revealed that CSF Aβ42, p- and t-tau levels significantly 
correlate with GFS in alpha and beta frequency bands. Specifically, lower CSF Aβ42 and 
higher p- and t-tau levels were associated with decreased GFS in fast frequencies (Table 3).  
Analysis of separate diagnostic groups revealed that significant associations of CSF AD 
biomarkers with GFP and GFS are dominantly present in MCI group, with a significant 
association with GFS beta present already in SCD patients.  
Table 3. Association between CSF biomarkers of AD, GFP and GFS in memory clinic patients.  
 
CSF = cerebrospinal fluid; GFP = global field power; GFS = global field synchronization. Data 
presented as β coefficients. Controlled for age, sex and MMSE.  *p < 0.05; **p < 0.01; ***p < 
0.001. Adapted with permission from Smailovic U, Koenig T, Kåreholt I, et al. Quantitative 
EEG power and synchronization correlate with Alzheimer’s disease CSF biomarkers. 
Neurobiol Aging. 2018;63:88-95. © 2017 The Authors. Published by Elsevier Inc. 
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5.2 PAPER II – EEG MICROSTATES IN HEALTHY ELDERLY AND MEMORY 
CLINIC PATIENTS 
The aim of study II was to investigate differences in EEG microstate topographies in healthy 
elderly, SCD, MCI and AD patients. The second aim was to investigate changes in microstate 
parameters in patients with different stages of cognitive impairment. The third aim was to 
investigate the association of microstate topographies and parameters with conventional CSF 
biomarkers of AD.  
The first finding was that the four representative grand mean maps from the healthy control 
group were compatible with the four normative maps available from the literature as well as to 
the maps from the previous studies employing microstate analysis (Figure 18) (178, 179).  
 
Figure 18. Four representative microstate maps from the healthy population published as 
normative data (age 6 – 80 years, on the left) and from healthy elderly controls from study II 
(60 – 93 years, on the right). Adapted with permission from Smailovic U, Koenig T, Laukka 
EJ, et al. EEG time signature in Alzheimer´s disease: Functional brain networks falling apart. 
Neuroimage Clin. 2019;24:102046. © 2019 The Authors. Published by Elsevier Inc. 
Study II further reported significant differences in microstate topographies between healthy 
elderly, SCD, MCI and AD patients for microstate classes A, C and D. Differences in 
microstate topographies between healthy elderly and memory clinic patients precluded direct 
comparison of microstate parameters between referred groups. Differences in microstate 
parameters (duration, occurrence, and contribution) were therefore investigated by back-fitting 
healthy elderly maps (serving as healthy controls) onto the patients’ EEG data (Figure 14). This 
analysis revealed a statistically significant increase in the duration of maps A and B 
(asymmetrical maps) and a significant decrease in the occurrence of maps C and D 
(symmetrical maps) with the more severe stage of cognitive impairment (comparing SCD, MCI 
and AD patients). Microstate contribution parameter resembles both duration and occurrence 
since it indicates the dominance of each map (expressed as the percentage) through the whole 
EEG recording. Mean contribution of maps A and B was significantly increased, while 
contribution of maps C and D significantly decreased with the more severe stage of cognitive 
impairment (Figure 19).  
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Figure 19. Contribution of healthy elderly microstate maps in the EEG of patients diagnosed 
with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease. 
Microstate contribution parameter indicates the dominance of each map (expressed as the 
percentage) through to whole EEG recording and therefore summarizes parameters such as 
microstate duration and occurrence. *p < 0.05. Adapted with permission from Smailovic U, 
Koenig T, Laukka EJ, et al. EEG time signature in Alzheimer´s disease: Functional brain 
networks falling apart. Neuroimage Clin. 2019;24:102046. © 2019 The Authors. Published by 
Elsevier Inc. 
Study II additionally reported a significant association between MMSE score and topography 
of microstate map A, CSF Aβ42 levels and the topography of microstate map C and CSF p-tau 
levels and topography of microstate map B when analyzed in the whole patient group. The 
direction of significant associations of microstate parameters with MMSE and conventional 
CSF biomarkers of AD followed the pattern of differences observed between SCD, MCI and 
AD patients (Supplementary data of study II).  
5.3 PAPER III – QEEG IMAGING IN RELATION TO [18F]FDG-PET 
Study III investigated the relationship between glucose hypometabolism in temporoparietal 
lobes, as evidenced by [18F]FDG-PET, and EEG LORETA functional connectivity measures 
within the same vulnerable brain regions in MCI and AD patients. The analysis was conducted 
in the whole cohort of clinically diagnosed MCI and AD patients and in the subgroup of CSF 
amyloid positive MCI and AD patients. The main finding was that decreased glucose 
metabolism in temporal and parietal lobes significantly correlated with decreased EEG 
instantaneous linear connectivity in alpha and beta frequency bands within the same vulnerable 
brain regions. Simultaneously, decreased [18F]FDG uptake in temporoparietal lobes 
significantly correlated with increased EEG lagged linear connectivity in slow frequencies, i.e. 
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delta and theta frequency bands, within the same vulnerable brain regions in MCI and AD 
patients. The pattern of referred [18F]FDG-PET and EEG connectivity correlations was 
consistent in the amyloid positive MCI and AD patients, especially when employing measures 
of EEG instantaneous connectivity (Figure 20).  
 
Figure 20.  Significant positive correlations between brain [18F]FDG SUVR and LORETA 
instantaneous linear connectivity in alpha and beta frequency bands in the corresponding 
brain regions of amyloid positive MCI and AD patients (based on CSF Ab42/40 ratio). *p < 
0.05. The regression line was fitted for visualization. 
5.4 PAPER IV – CSF NEUROGRANIN AND QEEG IN STABLE AND 
PROGRESSIVE MCI 
The main aim of study IV was to investigate the association between measures of global EEG 
power and synchronization and molecular synaptic marker neurogranin in the CSF of MCI 
patients. The second aim was to investigate their potential to predict clinical deterioration to 
AD dementia in MCI patients that have been followed-up for two years.  
Baseline neurogranin levels were significantly 
increased in the CSF of progressive compared 
to stable MCI patients (Figure 21). Quantitative 
EEG measure of global power, GFP, indicated 
significantly higher power in slow frequencies 
(delta and theta) in the progressive compared to 
stable MCI patients. 
Study IV further reported a significant 
negative association between CSF 
neurogranin levels and GFP and GFS in theta 
frequency band in the progressive MCI group, 
after controlling for age, sex, and CSF t-
tau/Aβ42 ratio.  
Figure 21. Baseline differences in CSF 
neurogranin levels in stable and progressive 
MCI patients. *p < 0.05. 
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The main finding of IV study was that CSF neurogranin, GFP theta and GFS beta were all 
significant and independent predictors of progression to AD dementia in MCI patients. GFP 
delta was close to the statistical significance (p = 0.059) and was further tested in the models 
that combined several predictors. GFP delta and theta were not assessed in the same model due 
to their strong correlation (r > 0.7). As a single predictor, GFP theta exhibited higher 
classification accuracy (74.6%) compared to CSF neurogranin (70.0%) or GFS beta alone 
(67.6%). A model that combined GFP delta or theta with GFS beta revealed both measures as 
significant predictors, however, the classification accuracy remained the same as for GFP theta 
alone (74.6%). A combination of CSF neurogranin, GFP theta and GFS beta reached the 
highest classification accuracy (81.4%) in differentiating progressive from stable MCI patients 
(Table 4).  
Table 4. Classification accuracy of baseline CSF neurogranin and qEEG measures in 
differentiating progressive from stable MCI patients. 
Significant predictor(s) CSF Ng GFP delta GFP theta GFS beta 
Classification 
accuracy 
CSF Ng *    70.0% 
GFP delta  (p = 0.059)   69.0% 
GFP theta   *  74.6% 
GFS beta    * 67.6% 
GFP delta + GFS beta  *  * 74.6% 
GFP theta + GFS beta   * * 74.6% 
CSF Ng + GFP delta * n.s.   74.3% 
CSF Ng + GFP theta *  *  74.3% 
CSF Ng + GFS beta *   n.s. 74.3% 
CSF Ng + GFP delta + GFS beta * *  * 78.6% 
CSF Ng + GFP theta + GFS beta *  * * 81.4% 
Logistic regression with CSF neurogranin, GFP and GFS as predictors and progression to AD 
dementia in MCI patients during two years follow-up as an outcome. CSF = cerebrospinal 
fluid; GFP = global field power; GFS = global field synchronization; Ng = neurogranin. N.s. = 
non-significant; *p < 0.05. Adapted from Smailovic U, Kåreholt I, Koenig T, et al. Synaptic 
molecular and neurophysiological markers are independent predictors of progression in 
Alzheimer’s disease. Manuscript under review. 
 
The dependence of CSF neurogranin and qEEG measures on patients’ baseline CSF Aβ42 
status (stratified according to the clinical cut-off for amyloid positivity < 550 ng/L) was 
additionally tested with interaction models, which revealed that these measures were 
significant predictors of progression to AD dementia independent of baseline CSF amyloid 





5.5 PAPER V – CSF NEUROGRANIN, AΒ42 AND TAU IN APP KNOCK-IN 
MOUSE MODELS 
Neurogranin has emerged as a potential CSF marker of synaptic pathology in AD. Study V 
assessed the translational potential of CSF neurogranin and its relationship to AD-related 
pathology (Aβ and tau) in the CSF and brain tissue of App knock-in mouse models. The 
experiments were performed on 12-months old App knock-in and wild-type control mice. 
Study V employed novel ultra-sensitive single molecule assay (Simoa) that allowed for several 
separate protein analyses from the limited amount of mouse CSF. 
The main finding was that neurogranin levels are increased in the CSF of App knock-in mouse 
models compared to age-matched wild-type controls (Figure 22). Additionally, study V 
revealed that AppNL-G-F mice have increased tau levels in the CSF (Figure 22). The Simoa 
analyses of brain tissue showed that tau levels are decreased in the soluble fraction of cortex of 
AppNL-G-F mice compared to wild-type controls. Simultaneously, increased CSF neurogranin 
levels correlated with decreased neurogranin levels in the soluble fraction of cortex when 
analyzed in App knock-in mice and age-matched wild-type controls. 
Study V further reported the relationship between AD CSF biomarkers in App knock-in mice 
that closely resembled the associations reported in clinical AD cohorts. These included a 
significant positive correlation of CSF neurogranin and CSF tau and a negative correlation of 
CSF neurogranin and CSF Aβ42 levels. Additionally, neurogranin and tau levels positively 
correlated in the soluble fractions of both cortex and hippocampus.  
 
Figure 22. CSF neurogranin and tau levels in the App knock-in mice models and age-matched 
wild-type controls. Data are presented as median and interquartile range. The Appwt/NL-G-F is 
presented in the figures for graphical comparisons but was not included in the statistical 
analyses. * p < 0.05. Adapted from Smailovic U, Delac L, Liman V, et al. Translational 
potential of Alzheimer’s disease CSF biomarkers from man to mouse – CSF neurogranin 
correlates with tau and amyloid-β pathology in App knock-in mouse models. Manuscript in 
preparation. 
An IHC staining protocol was established with the in-house developed anti-Ng antibody 
(corresponding to the antibody used in the Simoa assay) to investigate the expression of 
neurogranin in App knock-in mouse brain tissue (Figure 23). The first finding was the decrease 
in neurogranin immunostaining in the CA1 region of the hippocampus in the AppNL-F/NL-F and 
especially in AppNL-G-F/NL-G-F mice compared to Appwt/wt controls. The second finding followed 
double neurogranin – Aβ immunostaining and revealed loss of neurogranin immunoreactivity 
in the close vicinity of Aβ plaques in the hippocampus of App knock-in mice (Figure 23).  
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Figure 23. Fluorescent immunostaining for neurogranin in adult wild type mouse cortex and 
hippocampus using in-house developed anti-Ng Ng2 antibody (on the left). Double 
neurogranin – Aβ immunostaining and decreased neurogranin immunoreactivity around Aβ 
plaques in the AppNL-G-F/NL-G-F mice shown in higher magnification (on the right). Scale bars = 
100 µm. Adapted from Smailovic U, Delac L, Liman V, et al. Translational potential of 
Alzheimer’s disease CSF biomarkers from man to mouse – CSF neurogranin correlates with 





5.6 THESIS SUMMARY 
The general aim of the thesis was to contribute to the characterization of synaptic degeneration 
in Alzheimer’s disease. The main focus was on qEEG as a potential early, non-invasive, and 
readily available add-on to the assessment of synaptic dysfunction due to AD. The main 
conclusions can be summarized in the following points: 
• General EEG slowing and reduced global EEG synchronization correlated with 
decreased CSF Aβ42 and increased CSF p- and t-tau levels in memory clinic patients 
diagnosed with SCD, MCI and AD. 
 
• Topographies of EEG microstates deviated in SCD, MCI and AD patients compared to 
healthy elderly controls and were associated with changes in MMSE and conventional 
CSF biomarkers of AD. In memory clinic patients, EEG microstate parameters were 
altered in a gradient-like manner with the more severe stage of cognitive impairment. 
 
• EEG sLORETA analysis of brain functional connectivity detected AD-related regional 
dysfunction as evidenced by correlation and topographical overlap with [18F]FDG-PET 
findings of cortical glucose hypometabolism in MCI and AD patients. These findings 
were corroborated in a subsample of patients with the evidence of amyloid pathology.  
 
• qEEG measures of global power and synchronization and CSF synaptic marker 
neurogranin were independent predictors of progression to AD dementia in MCI 
patients. A combination of qEEG measures and CSF neurogranin increased the 
classification accuracy for differentiating progressive versus stable MCI patients. 
 
• App knock-in mouse models of AD exhibited increased neurogranin and tau and 
decreased Aβ42 levels in the CSF. Neurogranin levels interrelated in the CSF and brain 
tissue and were associated with Aβ pathology. Relationships between CSF biomarker 
alterations were similar to the patterns found in clinical AD cohorts. In parallel use of 
mouse CSF biomarkers and App knock-in models have translational value for 






6.1 ALZHEIMER’S DISEASE CONTINUUM – IMPORTANT CONSIDERATIONS 
Most of the studies presented in the thesis included patients on a whole spectrum of cognitive 
impairment, even though a significant proportion of SCD and MCI patients will not progress 
to AD or other types of dementia. However, this type of “all-inclusive” analysis was performed 
for several reasons. First, there may not be strict transition points in pathological biomarker nor 
cognitive status since it was postulated that AD develops on a pathological-clinical continuum 
(6). Therefore, including patients on the whole continuum may be crucial when it comes to the 
investigation of a relationship between different molecular and functional markers. Second, 
cut-offs for conventional biomarker changes, such as for CSF Aβ42 positivity, are often set for 
clinical diagnosis of AD dementia and possibly require more lenient thresholds in intermediate 
stages such as SCD and MCI. Otherwise, a certain proportion of subjects may be neglected as 
representing a non-AD trajectory even though the biomarker values were showing abnormal 
trends towards or close to cut-off values for AD dementia (261, 262). Third, the results can be 
further substantiated by a sub-analyses in separate, biomarker defined, diagnostic groups as it 
was performed in the present thesis. It is also important to note that while molecular and 
imaging biomarkers are undeniably important for both research and clinical investigations, 
their use is still restricted to the large medical centers. Studies with well-phenotyped naturalistic 
cohorts are therefore crucial for the validation of novel biomarker candidates. At the same time, 
the use of clinically defined diagnostic groups warrants caution due to the enrollment of 
etiologically heterogeneous patient groups. Therefore, it is important to consider regular 
clinical follow-ups as well as biomarker dynamics in SCD and MCI patients in future large-
scale qEEG studies.  
6.2 DEMENTIA ASSESSMENT – WHERE DOES EEG STAND? 
The European Federation of Neurological Societies (EFNS) guidelines suggest that EEG may 
aid differential diagnosis of AD (263). EFNS guidelines highlight the use of EEG in the case 
of suspected Creutzfeldt-Jakob Disease, toxic metabolic disorders, and transient epileptic 
amnesia (263). Its contribution to the differential diagnosis of dementia was further supported 
by the recent consensus criteria from Dementia with Lewy Bodies (DLB) Consortium which 
include EEG findings of dominant posterior slow-wave EEG activity as a supportive biomarker 
for DLB (264). Guidelines from National Institute for Health and Care Excellence (NICE), 
UK, explicitly state that EEG should not be used to diagnose AD (265). Lack of clinical 
recommendations for the use of EEG in the assessment and diagnosis of AD stem from the 
insufficient evidence of its pathological and clinical validity as well as lack of standards in 
reporting research findings. Furthermore, the nature of EEG signal made it appealing for 
different algorithmic approaches and an enthusiastic introduction of numerous qEEG 
measures. While the complexity and variability of EEG signal call for a comprehensive 
analytical approach, research has often been method-driven and outside the context of 
underlying disease pathologies, leaving the question where does the EEG stand in the dementia 
assessment largely unresolved. The present thesis attempted to shed light on these issues, such 
as the need for different EEG domain analyses, the relation of qEEG markers to AD pathology 
and the prognostic potential of qEEG measures in the context of AD, as discussed throughout 
the following sections.   
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6.3 IS THERE A NEED FOR DIFFERENT QEEG DOMAIN ANALYSES? 
Most EEG studies so far have reported generalized EEG slowing in patients along AD 
continuum, resulting from the EEG power spectral analysis, which was also confirmed in the 
present thesis. Even though power spectra analysis captures disturbances across different 
frequency bands that bear physiological significance, it may not fully portray the extent of brain 
functional impairment. Additionally, frequency domain analysis does not utilize everything 
that qEEG, as a method, has to offer. The present thesis employed qEEG analyses in frequency 
(study I, III and IV), time (study II) and space domain (study III). Study I and IV employed 
more conventional analyses and measures of global EEG power and synchronization that have 
been previously investigated in comparable studies and large memory clinic cohorts (148, 158, 
166). In the present thesis, these qEEG measures were further evaluated in relation to the 
conventional CSF biomarkers of AD (study I), synaptic CSF marker neurogranin and their 
potential to predict clinical deterioration in MCI patients (study IV). Study II involved EEG 
microstate analysis in the time domain that may capture the (dis)organization of large-scale 
resting-state brain networks in AD. In contrast to other methods, the discovery of microstates 
has opened a possibility to detect and study disturbances in spontaneous mental processes with 
a uniquely high time resolution (176, 179). Additionally, study II involved EEG recordings 
from a large group of healthy elderly controls that may serve as normative data for future EEG 
and microstate analyses in brain aging studies. Study III further investigated the association 
between cortical glucose hypometabolism, as evidenced by [18F]FDG-PET, and EEG 
functional connectivity measures in MCI and AD patients. In order to detect the topographical 
sources of brain functional disturbances, an EEG imaging (LORETA) analysis was employed. 
LORETA has been previously validated against other imaging modalities and employed in 
studies involving cognitively impaired patients (190-192, 195, 266). Altogether, the choice of 
qEEG methods was fitted to the study design, involving different diagnostic modalities, and 
research questions of interest. Recent studies have additionally emphasized the advantage of 
combining multiple EEG markers when it comes to the diagnostic classifiers of AD and 
prediction of clinical progression of the disease (267-269). Altogether, and taking into account 
the inter-individual variability in EEG signal, integrating different qEEG methods may be 
necessary for a comprehensive assessment of different aspects of functional (synaptic) deficits 
due to AD. 
6.4 TOWARDS VALIDATION OF QEEG WITH MOLECULAR AND 
NEUROIMAGING MARKERS 
The diagnosis of dementia has several challenges, among which are the different etiologies 
underlying clinically evident cognitive deficits. Therefore, it is important to relate novel 
diagnostic approaches to the available AD biomarkers and disease-associated neuropathology. 
In addition, biological substrates of the qEEG alterations observed in AD patients have not 
been extensively investigated in large and well-defined clinical cohorts so far. The present 
thesis investigated the association of conventional CSF biomarkers of AD (study I and II), 
[18F]FDG-PET (study III) and novel CSF synaptic marker neurogranin (study IV) with qEEG 
in cognitively impaired subjects and patients with AD. The main finding of study I was the 
distinctive pattern of associations between qEEG power abnormalities and CSF markers, i.e. 
the association of decreased CSF Aβ42 levels with increased EEG delta and theta power and 
the association of increased CSF p- and t-tau levels with decreased EEG alpha and beta power 
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in SCD, MCI and AD patients. While the study presented some encouraging findings when it 
comes to the use of qEEG in patients along the AD continuum, it should be noted that EEG, as 
a method, cannot be offered as a substitute for molecular diagnostic tests for specific brain 
pathologies. However, the study provided insight into potential pathological changes 
associated with observed alterations in EEG power spectra that have been long related to AD. 
Furthermore, these findings may contribute to the selection of qEEG features that may help 
differentiate AD from non-AD pathologies as causes of cognitive impairment. Study III further 
investigated the association of cortical glucose metabolism with qEEG measures of brain 
functional connectivity indicating that EEG imaging methods, such as LORETA, have the 
potential to detect functional disconnection of AD vulnerable brain regions. Despite moderate 
correlations and the need for further validation in larger cohorts, these findings have several 
implications. First, alterations of qEEG measures of brain functional connectivity observed in 
AD were associated with specific brain regional dysfunction as evidenced by typical [18F]FDG-
PET pattern of decreased glucose metabolism in temporoparietal lobes in MCI and AD 
patients. Second, these findings further support the potential role of qEEG as a marker for 
synaptic alterations in AD since [18F]FDG uptake was shown to be closely related to synaptic 
density and function (110, 123, 270). Third, the utility of [18F]FDG-PET to differentiate AD 
from other types of dementia and the relationship between cortical glucose metabolism and 
cognitive reserve in preclinical AD (271-273) hints that qEEG may find a similar clinical 
application. In study IV, qEEG measures of power and synchronization in theta frequency band 
were negatively associated with CSF neurogranin levels in the MCI group progressing to AD 
dementia. Interestingly, the association between increased CSF neurogranin levels and 
decreased GFP in theta band was significant only after controlling for CSF t-tau and Aβ42 
levels. This should be further investigated in order to disentangle the effects of neuronal injury 
and possible neuronal compensatory mechanisms in MCI patients. Lastly, the direct 
relationship of qEEG abnormalities with AD pathology may be explored in preclinical models 
of the disease. In that context, emerging studies on fluid, imaging and neurophysiological 
markers in animal models offer a possibility to assess biomarker inter-relations as well as their 
direct link to the core AD neuropathology. 
6.5 TRANSLATIONAL PERSPECTIVE – SYNAPTIC DYSFUNCTION IN AD 
MOUSE MODEL 
Translational biomarkers of AD may facilitate the selection of relevant preclinical models, 
investigation of their direct correlates with neuropathology and therefore different disease 
mechanisms, and eventually selection of novel drug candidates. Study V reported an increase 
in CSF neurogranin, an emerging marker of AD synaptic pathology according to the clinical 
studies, in App knock-in mouse models of AD. Neurogranin levels in the brain tissue 
interrelated with its CSF levels and were affected by the presence of Aβ plaques. These 
findings implicate that neurogranin alterations in the CSF and brain tissue are downstream to 
the accumulating amyloid pathology. Additionally, it puts forward neurogranin as a potential 
translational marker of synaptic pathology due to AD. While mouse CSF experiments require 
a surgical procedure that provides a limited amount of the sample for further analyses, the 
use of novel ultra-sensitive assays for protein quantification opens a possibility for 
simultaneous investigation of several relevant biomarkers from the small quantity of CSF 
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specimens. This suggests in parallel use of fluid biomarkers as a translational bridge between 
preclinical and clinical AD research. 
Interestingly, study V further reported an increase in tau levels in the CSF of App knock-in 
mice, a model of β-amyloid pathology in AD. This finding is in line with some previous 
studies on transgenic mice models of amyloid-β pathology, such as APP/PS1 and APP23, 
that reported increase in CSF tau levels compared to age-matched wild-type controls (274). 
None of these models of amyloid-β pathology develop considerable tau 
hyperphosphorylation, NFTs or neuronal loss. The inconsistencies between tau pathology in 
the brain and CSF tau levels were previously reported in the clinical studies that included 
CSF investigations of autopsy-confirmed AD cases (275) as well as in patients with 
tauopathies (79). More recently, tau release into the extracellular space was shown to be 
directly associated with the level of brain synaptic activity (276, 277). Even though amyloid-
β was shown to alter synaptic activity in AD (278), further studies are warranted to investigate 
the exact mechanisms and pathways behind amyloid-induced tau pathology in AD (279).  
The aim of the preliminary study introduced in this thesis is to evaluate changes in synaptic 
function, assessed by EEG recordings, in App knock-in mouse models. The study will evaluate 
longitudinal changes in EEG power spectrum in relation to the accumulating Aβ pathology. 
The recordings from epidural electrodes as well as analyses of quiet wake vigilance state 
facilitate the translational perspective of the project. Interestingly, a recent study reported 
decreased power in lower frequencies (delta and theta) and increased power in higher 
frequencies (alpha and beta) in a previous generation of transgenic mouse models of amyloid-
β pathology (280). These findings seem to be in direct contrast to the reports from qEEG 
analyses in patients with AD, even though the study did not assess longitudinal EEG changes 
that could detect the emergence of different phenotypes as transgenic mice age. The 
longitudinal qEEG analysis in App knock-in mice may therefore elucidate the relationship 
between amyloid accumulation and neurophysiological findings in AD, in the absence of 
substantial tau pathology and neuronal loss.  
Results showing CSF biomarker changes in App knock-in mice models encourage their use in 
the translational studies of synaptic degeneration and core pathophysiological mechanisms of 
AD, including potential drug candidate testing. Nonetheless, the limitations of these preclinical 
models should be recognized, such as the lack of some hallmark aspects of AD pathology and 
the introduction of a combination of mutations that are found in the different familial and not 
sporadic, the most common form of the disease. 
6.6 PREDICTIVE VALUE OF SYNAPTIC MARKERS 
An integrated approach to dementia diagnosis calls for the use of interdisciplinary tools that 
would provide a comprehensive assessment of structural and functional deficits due to AD. In 
this context, potential of the diagnostic tests to identify subjects with high risk for rapid 
deterioration to AD dementia is of main importance. Study IV investigated the relationship 
between molecular and functional synaptic markers, i.e., CSF neurogranin and qEEG measures 
and whether they have any additive value in predicting progression to AD dementia in MCI 
patients that have been followed-up for two years. The results showing that CSF neurogranin 
and qEEG measures of global field power and synchronization are all significant predictors of 
progression to AD dementia implicate that these markers provide complementary information 
 
 53 
about synaptic degeneration in AD. Extensive phenotyping of synaptic damage due to AD may 
be warranted for reliable identification of subjects and patients that are at risk to decline to AD 
dementia and have a faster progression of the disease. This was further corroborated by 
showing that a combination of CSF neurogranin and qEEG measures increased the 
classification accuracy of cases identified as progressive versus stable MCI, compared to the 
use of individual markers. Another interesting finding was that CSF neurogranin and qEEG 
measures were predictors of progression to AD dementia irrespective of the patients’ baseline 
amyloid status. These results are seemingly in contrast to the previous reports showing that 
CSF neurogranin and t-tau are primarily associated with clinical deterioration in the presence 
of Aβ pathology (220). However, the referred study conducted separate analyses in CSF Aβ42 
positive and negative subjects, which was precluded by the smaller sample size in study IV. 
Another explanation may be related to the inclusion of MCI patients only (study IV), where 
these associations may not be as pronounced compared to the analyses conducted in patients 
covering the full spectrum of the disease, as well as the use of conservative clinical cut-offs for 
CSF Aβ42 positivity. Altogether, complementarity and additive value of different synaptic 
markers in predicting AD dementia call for multimodal phenotyping of synaptic damage due 
to AD. These results require further validation in larger cohorts including healthy subjects and 
patients with clinically- and biomarker-verified diagnoses, thorough neurophysiological 





7 FUTURE PERSPECTIVES 
The research criteria for AD diagnosis has emphasized the importance of biomarker inclusion 
into the diagnostic process in order to ascertain the underlying pathophysiology and cover the 
full continuum of the disease (60). Recent advancements in molecular imaging and fluid 
biomarkers provide a unique opportunity to in vivo assess pathological changes associated with 
AD. However, there is a certain concern regarding their widespread clinical use. In addition, a 
considerable number of healthy elderly show amyloid positivity (281) and stable cognitive 
status over a long period of time despite abnormal core markers of the disease pathophysiology 
(282). Disclosing such clinical findings to the patients and healthy elderly raises many ethical 
considerations (283, 284). In this regard, an accurate assessment of the risk of disease 
progression and estimated time to transition to the next clinical stage are of great priority for 
patients, their families, and clinicians. Quantitative EEG is a non-invasive, low-cost, and 
widely accessible technique that could contribute to the multimodal assessment of the 
individual brain functional status and risk for impending cognitive deterioration. EEG shows 
relatively high inter-individual variability (285, 294), and lacks sensitivity and specificity of 
molecular markers (286), however, it provides a “window” into the complex brain functioning 
that is influenced by many genetic, pathologic and environmental factors (287). Recent 
identification of numerous low-risk genes that affect different AD pathways and contribute to 
the late onset AD (288) supports the utility of “umbrella” diagnostic and prognostic classifiers. 
However, several additional research and clinical considerations should be addressed before 
establishing the potential role of qEEG in a clinical work-up of dementia.  
In addition to the standardized recording setup and preprocessing approaches, there is a need 
for the use of harmonized qEEG measures across studies at different research centers. So far, 
numerous qEEG approaches and measures of brain functional connectivity, the topography of 
cortical activity and microstate algorithms and sorting procedures have been utilized in AD 
research field, most of which have not replicated methodological approaches used in 
complementary studies.  
In this context, initiatives for freely available and multi-center EEG datasets would aid 
methodological harmonization of EEG research studies. It would expedite collection, 
utilization and validation of the data and open a possibility for the coordinated use of data from 
large normative cohorts and other contrast diagnostic groups. 
A significant proportion of cognitively impaired patients are on a different clinicopathologic 
spectrum of dementia with underlying mixed and other types of neurodegenerative processes 
(289-292). Several studies aimed to investigate resting-state EEG as a potential tool in the 
differential diagnosis of dementia. To date, EEG is included as a supportive diagnostic 
biomarker for DLB (264). Quantitative EEG abnormalities in time, frequency and space 
domain that were reported in patients along the AD continuum in the present thesis, however, 
await further validation in the studies involving contrast groups such as patients diagnosed with 
frontotemporal dementia (FTD), DLB and mixed dementia with both neurodegenerative and 
cerebrovascular pathology. Another important role of biomarkers in the context of biological 
heterogeneity of the disease is the detection of entities that comprise the clinical AD continuum 
but have considerably different clinical outcomes, such as primary age-related tauopathy (292, 
293). The genetic basis of variation in individual EEG was supported by studies that showed 
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high concordance in EEG signal between monozygotic twins (294, 295). It would thus be of 
interest to additionally assess the utility of qEEG in patients with fAD, including pre-
symptomatic mutation carriers.  
Investigation of EEG phenotypes in animal models of AD will further disentangle the 
association between neurophysiological abnormalities and molecular pathology underlying the 
disease. It will additionally aid the selection of animal models with relevant neurophysiological 
phenotypes for AD translational studies. Overall, in parallel use of qEEG and fluid synaptic 
biomarkers in future preclinical and clinical studies on synaptic dysfunction in AD would 
expedite the translation of preclinical findings to clinical use. 
Relatively large inter-individual variability in EEG signal and reported abnormalities across 
several qEEG domains in AD suggests the use of a combination of EEG features for the 
improved diagnostic and prognostic accuracy of AD. In addition, applying more advanced 
statistical models may improve the selection and classification performance of qEEG markers. 
So far, encouraging results were obtained by using automated tools and integrating multiple 
EEG markers for the diagnostic classification of AD (267-269). Future studies may elucidate 
the optimal combination of the EEG features, such as measures of power spectra, instantaneous 
and lagged connectivity, microstate topographies and parameters that may provide 
comprehensive information on synaptic dysfunction due to AD. Additionally, the utility of 
EEG in dementia assessment may go beyond resting-state EEG. Disturbances in sleep 
architecture were shown to be indicative of future cognitive decline and dementia in MCI 
patients (296), highlighting the potential use of sleep EEG recordings and analysis. 
The validity of qEEG as a synaptic marker in AD will be further assessed in studies combining 
several novel CSF pre- and postsynaptic markers as well as synaptic SV2A PET imaging. 
However, the purpose of multimodal studies goes beyond interrelating novel and established 
markers of AD. Multimodal approaches that combined EEG with other imaging and molecular 
markers were shown to significantly improve the differential diagnosis of AD (297-300) and 
may be therefore not just advantageous, but necessary in the diagnostic work-up of dementia. 
These notions require further investigations, however, in these circumstances, qEEG could be 
applied as a diagnostic add-on at multiple time points starting from the early stages of the 
disease. In addition, qEEG may reflect the functional deficits in patients with different levels 
of cognitive reserve and possibly aid the differentiation of AD from other causes of cognitive 
impairment.  
Clinically silent epileptiform activity, as a manifestation of brain network hyperexcitability, 
was reported in early pre-dementia stages of the disease (301), suggesting interventions with 
available treatment options that were not initially approved for AD. The potential of 
anticonvulsant levetiracetam, a modulator of SV2A, to improve cognitive deficits in MCI and 
AD patients is currently being tested in clinical trials (302, 303). These recent clinical drug 
trials incorporate EEG as a part of the baseline assessment battery as well as the secondary 
outcome measure. In addition to the currently established AD biomarkers, EEG may therefore 
aid the selection of patients that may benefit from the novel pharmacological interventions as 




Overall, the findings of the present thesis indicated plausible associations between qEEG 
measures and molecular and functional markers of AD. It addressed the importance of 
comprehensive analyses across several EEG domains and harmonized use of qEEG markers in 
the context of AD research. The results further suggested complementary value of molecular 
synaptic and qEEG markers in predicting cognitive deterioration to AD dementia in memory 
clinic patients that are at risk for cognitive decline. Ultimately, the results of the thesis invite 
for the research and clinical validation of multimodal synaptic markers for early AD diagnosis, 
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